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ABSTRACT
Many environmental mutagens and chemotherapeutic agents exert their
biological effects by damaging DNA. An important determinant of cellular
response to DNA damage is the location and quantity of damage. Therefore, the
goal of my thesis research is to elucidate those mechanisms that govern how
genotoxins select their DNA targets in cells.
To this end, I have performed studies to identify how the cellular
environment of DNA modulates damage produced by three enediyne antitumor
antibiotics: esperamicin Al, esperamicin C and calicheamicin yI. Using a
modified ligation-mediated PCR (LMPCR) technique, DNA damage along the
human phosphoglycerate kinase (PGK1) promoter was mapped. The results show
that location and quantity of the DNA damage are affected by nucleosomes,
transcription factors and DNA methylation. Nucleosome cores in the inactive
PGK1 promoter suppressed DNA damage produced by esperamicin Al (an
intercalator) but not by esperamicin C and calicheamicin (both minor groove
binders). Transcription factors in the active PGK1 promoter suppressed damage
by esperamicin Al, but only minor groove binding transcription factors
suppressed damage by esperamicin C and calicheamicin. Some major groove
binding factors even enhanced damage caused by esperamicin C and
calicheamicin. Enhancement of damage was also observed with all three
enediynes between transcription factor binding sites. In addition, cytosine
methylation enhanced DNA damage made by esperamicins. These results are
consistent with a model in which target accessibility, DNA dynamics, DNA
bending and minor groove width are important factors affecting enediyne target
selection in vivo. Finally, a technique was developed to isolate DNA damage
fragments produced by nanomolar calicheamicin concentrations. The technique
can potentially be used to map low levels of DNA damage in the entire genome.
This work extends our in vitro observations of enediyne target selection to
the complex milieu of the whole cell. These results lay the foundation for
understanding target selection mechanisms of other genotoxins in vivo.
Thesis Supervisor: Peter C. Dedon
Title: Associate Professor of Toxicology
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CHAPTER 1
INTRODUCTION
The integrity of DNA is critical not only for the viability but also for the
functional activity of all organisms. However, cellular DNA is constantly
subjected to a variety of potentially harmful insults, from both endogenous
and exogenous agents (reviewed in [1]). The endogenous sources include
spontaneous depurination and cytosine deamination, as well as reactions
with oxidants and alkylating agents generated during cell metabolism [2].
The exogenous sources include chemicals (such as aflatoxin B1) and physical
agents (such as UV light and y-radiation). Damage to the cellular genome has
also been used as a double-edged sword for the treatment of cancer, since
destruction of cancer cells is an intended outcome in cancer chemotherapy.
The DNA damage caused by drugs and toxins, if unrepaired, can lead to cell
death or DNA mutation. The premise for my thesis research is that the
location and quantity, i.e., the target selection of the damage, plays an
important role in determining the cellular response to DNA damage.
Therefore, the goal of my thesis research is to elucidate those mechanisms
that govern how genotoxins select their DNA targets in cells.
To this end, I have performed studies to identify how the cellular
environment of DNA modulates the distribution of DNA damage produced
by genotoxins. Using enediyne antitumor antibiotics as model genotoxins, I
focused on the following aspects of the cellular environment of DNA:
nucleosomes, transcription factors and DNA methylation. In the following
chapters, I will first provide an overview of the subject matter (Chapter 1) and
describe a technique to map enediyne-induced DNA damage at single-
nucleotide resolution in a single-copy gene in mammalian cells (Chapter 2). I
will then examine these three aspects of the cellular environment of DNA in
greater detail (Chapters 3-5). Finally, I will move beyond a single-copy gene
and describe a genome-based technique that can potentially be used to map
low levels of DNA damage in the genome (Chapter 6).
I. Cellular Environment of DNA
DNA in mammalian nuclei is packaged along with various proteins
into the compact mass of chromatin [3, 4]. For reasons of simplicity, most
genotoxin-DNA interactions have been studied with purified (protein-free)
DNA in vitro. However, chromatin is the true target for genotoxins and the
packaging of DNA as chromatin may affect the target selection by genotoxins.
One of the most important goals of my thesis research has been to understand
how genotoxins select their targets in cells compared to naked DNA.
Many factors of DNA structure, dynamics, and accessibility in
mammalian nuclei may interact collectively with genotoxin structure to
determine which targets are selected in vivo (Figure 1.1). These factors
include sequence selectivity, methylation modification, binding of
transcription factors and other nucleoproteins, nucleosome structure, and
high order chromatin folding (Figure 1.1). In the following introduction, I
will discuss these factors in order of increasing organizational complexity,
from naked DNA to nuclear architecture.
A. Sequence Context in Naked DNA
Duplex DNA exemplifies the union of similarity and diversity in life.
While the sugar-phosphate backbone of DNA remains chemically conserved
throughout evolution, differences in base sequence are fundamental to the
vast diversity in all life forms. Sequence context and its related structure and
dynamics in DNA form the bases for sequence-specific interactions with
proteins as well as sequence-dependent interactions with genotoxins.
A genotoxin can interact with duplex DNA in two primary ways that
are significantly different (Figure 1.1):
1) groove-binding interactions which involve direct contact of the bound
molecule with the edges of base-pairs in either of the (major or minor)
grooves of DNA; and
2) intercalation of planar or approximately planar aromatic ring systems
between base-pairs.
Regarding the former, the major and minor grooves differ significantly
in electrostatic potential, hydrogen-bonding characteristics, steric effects, and
hydration [5]. Many proteins exhibit binding specificity primarily through
major groove interactions while small genotoxins in general prefer the
minor groove. Any specificity which arises in the binding comes from
contacts between the bound molecule and the edges of the base pairs on the
"floor" of the groove. Intercalation results from rotation about torsional
bonds in the DNA backbone, separation of base-pairs, and insertion of a
planar or near planar molecule in between base-pairs. DNA is unwound at
the site of an intercalation complex and the normal approximately 361
rotation of one base-pair with respect to the next is decreased as a result of
intercalation [5].
In comparing groove-binding and intercalating genotoxins, it is clear
that the groove-binders, as a class, display significantly greater binding
selectivity than intercalators. Intercalation cavities created at A:T or at G:C
base-pairs are quite similar in their potential for interaction with planar
aromatic ring systems. Electrostatic, van der Waals, hydrophobic, etc.
contributions to binding are similar for the two sites. On the other hand,
groove-binding molecules can contact more base-pairs as they lie along the
groove in a DNA helix and thus have more selectivity in terms of sequence
context [5].
Using enediyne antitumor antibiotics as model genotoxins, I have the
opportunity to compare and contrast the effects of these two types of DNA
interactions on genotoxin target selection (see section II of this chapter).
B. DNA Methylation
In mammalian cells, DNA is covalently modified by attachment of
methyl groups to the C5-position of the cytosines in CpG dinucleotides.
Cytosine methylation has significant biological functions in mammalian
development, including genomic imprinting and X-chromosome
inactivation (reviewed in [6]). Abnormalities in the distribution of
methylated sites on DNA may contribute to the pathogenesis of certain
human diseases, such as fragile X syndrome and cancer [6].
Fundamental to these biological functions is the ability of some
methylated CpG repeats to suppress transcription [7]. Two mechanisms may
underlie such gene silencing phenomena: site-specific methylation may
decrease the binding of essential transcription activators, or enhance the
binding of transcription inhibitors. Regarding the first hypothesis,
methylation at a CpG site centrally located within the recognition sequence of
a HeLa cell transcription factor strongly inhibited both the factor binding and
gene transcription (e.g., [8]). This hypothesis also forms the basis for the
methylation interference assay (e.g., [9]), although not all transcription factors
are affected by DNA methylation [10]. Meanwhile, the discoveries of methyl-
CpG-binding proteins, MeCP1 [11] and MeCP2 [12], their inhibitory effects on
transcription [13], and their location in heterochromatin [14] all strongly
support the second mechanism in vivo.
The observation that methylated DNA alters the binding of proteins
essential in transcription regulation underscores the changes in DNA
structure that occur upon CpG-methylation. First and most obvious, the C5-
methyl groups protrude into the major groove, where most regulatory
proteins contact DNA. Secondly, cytosine methylation causes many more
subtle changes in DNA structure and dynamics that include helical
unwinding [15], increased based stacking and helical stability [16], reduction
in major groove charge density near the methyl group [17] and, in certain
sequence contexts, modulation of DNA bending [18-20]. Such structural
changes may be the bases of altered protein interactions with methylated
DNA.
Similar to the relationship between proteins and methylated-CpG
sequences, the interactions of genotoxins with methylated DNA may also be
altered. Both benzo[a]pyrene diol epoxide [21] and mitomycin C [22] show
enhanced reactivity with methylated sequences, while damage produced by
bleomycin [23] and N-methyl-N-nitrosourea [24] is inhibited by cytosine
methylation.
I have examined the effect of DNA methylation on enediyne-mediated
DNA damage in Chapter 5, with an emphasis on the relationship between
genotoxin structure and methylation effects.
C. The Nudeosome
Human cells contain -1 m of DNA packaged into a nucleus with a
diameter of 5-10 grm. To accomplish this 10s-fold reduction in length while
maintaining functionality, nuclear DNA is organized into a hierarchy of
chromatin structures with over 100 different proteins. The main constituents
of nucleoproteins in eukaryotes are a class of highly basic proteins known as
histones, which consist of five distinct subtypes: H4, H3, H2A, H2B and H1. In
addition to histones, a heterogeneous group of proteins with high cell-type
specificity is present in the nucleus. These proteins, which are grouped
simply as nonhistone proteins, consist of several hundred different proteins,
most of which are present in trace amounts [3].
The highest level of chromatin structure divides the genome into two
distinct forms: heterochromatin, containing transcriptionally silent DNA,
and euchromatin, which represents transcriptionally competent DNA [3].
Not all genes are packaged to the same level of compaction inside eukaryotic
nuclei. Transcriptionally inactive genes in heterochromatin are more
compacted than active genes. The latter are characterized by a more open
chromatin structure and the presence of a variety of nonhistone proteins
essential for the regulation and maintenance of transcription.
At the base of this organization is the nudeosome, a structure common
to both hetero- and euchromatin [3, 4]. The canonical nucleosome consists of
two regions: core and linker. The core is composed of 146 base pairs (bp) of
DNA wrapped twice into a left-handed superhelix around an octamer of
histone proteins consisting of pairs of histones H2A, H2B, H3 and H4. The
structure of a nucleosome core particle, crystallized under physiological
relevant ionic conditions, was recently solved by X-ray crystallography at 2.8 A
resolution [25], a significant improvement over previous studies [26]. One of
the most important findings to emerge from this three-dimensional analysis
was that the DNA does not take a perfectly regular path in winding about the
histone octamer. Instead, the double helix is bent fairly sharply at several
specific locations. The histones interact with the phosphodiester backbone on
the inner face of the DNA superhelix, with the 146 bp of the core DNA
contacting the histone octamer in the following order: H2A, H2B, H4, H3, H3,
H4, H2B, and H2A. Thus, a nucleosome has a dyad axis of psedo-symetry
with two sharp bends flanking an S-shaped jog of the DNA at the dyad axis.
The bends occur adjacent to points of substantial contact between the DNA
and histones H3 and H4. At these sites, the regular B helix conformation is
distorted over several neighboring base pairs rather than being kinked
abruptly [25]. Another finding was that DNA in nucleosome core is
overwound compared to protein-free DNA. The helical repeat of DNA in
nucleosome core is 10.2 bp/turn compared to 10.5 bp/turn in the canonical B-
form DNA in solution [27].
Depend on the mode of interaction with duplex DNA, various
genotoxins may recognize nucleosomal DNA differently. DNA minor
groove binders can bind to DNA in nucleosome core at sites where the minor
groove faces away from the core histones, while intercalator binding is
restricted to the linker regions [28]. The reduced binding of intercalators to
nucleosome core DNA is most likely caused by constrained DNA dynamics
due to histone-DNA contacts [29-32].
I have examined the effect of nucleosome structure on enediyne-
mediated DNA damage in a model gene in vivo (Chapter 3), with an
emphasis on the relationship between genotoxin structure and DNA
conformation in nucleosomes.
D. Higher Order Chromatin Structure in Transcriptionally Inactive Genes
In transcriptionally inactive DNA in interphase nuclei, the linear array
of nucleosomes is further folded into high order chromatin structures.
According to the currently accepted models, a string of nucleosomes is folded
into a solenoid fiber containing six nucleosomes per turn and a diameter of
300 A. This superhelical structure is stabilized by histone H1, which contacts
linker DNA [3].
According to the loop model of genomic organization, 104 - 10 bp loops
of solenoidal chromatin in interphase nuclei have their bases attached to a
nucleoprotein/RNA scaffold called the nuclear matrix [33]. During mitosis,
the matrix takes the form of a metaphase scaffold with chromatin loops
arranged spirally around the scaffold to form the arms of chromosomes [34].
This provides the highest level of compaction of DNA.
The structure of a canonical nucleosome is well understood because of
the high resolution crystallographic studies [25]. However, the exact way that
nucleosomes are folded into higher order chromatin structure is not as clear.
The solenoidal structure in the 300 A fiber is the most accepted model, but
other models do exist [3]. The exact mechanism by which the 300 A solenoid
fiber forms chromatin loops is even less certain [35].
As in the nucleosome structure, higher order chromatin compaction is
expected to affect interactions with genotoxins. However, currently there is
no good method to quantitatively map DNA damage in a region beyond the
size of 10' bp. Depending on the level of selectivity of a genotoxin, mapping
DNA damage in 10' bp of the human genome is a daunting task. However,
in Chapter 6, I will present a technique that allows such issues to be addressed
at physiologically-relevant levels of genotoxin-induced DNA damage.
E. Transcriptionally Active Chromatin
The hierarchical organization of transcriptionally inactive chromatin
presents a problem for proteins involved in DNA metabolism. During DNA
transcription, interphase chromatin must undergo local decondensation to
allow the access of transcription factors and the passage of transcription
machinery. Therefore, transcriptionally active chromatin has a more open
structure than its inactive counterpart. So far, four major differences between
active and inactive chromatin have been reported: (1) acetylation of histones,
(2) depletion of H1, (3) chromatin remodeling factors, and (4) transcription
factor binding. I will address each of them briefly.
1. Acetylation of histones
Histones in transcriptionally active chromatin are hyperacetylated
compared to inactive chromatin [3, 4, 36]. The acetylation of the positively
charged E-amino groups of lysines has been proposed to neutralize
electrostatic interactions between the histones and the phosphodiester
backbone, and thus reduce contacts between histones and DNA [35, 37].
Recently, histone acetylation was found to be a prerequisite for
transcription rather than a downstream effect of transcription. Hebbes et al.
demonstrated that hyperacetylation was associated with genes poised for
transcription rather than those that are actively transcribing [38]. In addition,
the discovery that acetyltransferases form complexes with certain
transcription factors provides a mechanism by which the appropriate region
of chromatin (i.e., transcription factor binding region) can be targeted for
"remodeling" [39]
2. Depletion of histone Hi
Many studies have shown a deficiency of linker histones in
transcriptionally active regions of chromatin (reviewed in [40]). The
conclusion from these studies is that linker histones are present on
transcribed or transcribable genes to a much reduced extent, in some cases by
as much as 50%. Several other studies indicate an inverse relationship
between transcriptional activity and linker histone content [40].
The linker histone H1 is important for the formation of the condensed
300 A fiber [3]. Thus, the partial depletion of H1 in active chromatin may
facilitate the formation or maintenance of active chromatin.
3. Action of chromatin remodeling factors
Nucleosome remodeling triggered by a primary transcription factor is a
prerequisite in many promoters for the binding of additional factors and the
assembly of transcription machinery (reviewed in [41]). However, in many
systems additional protein factors are required that utilize energy from
adenine triphosphate (ATP) to remodel nucleosomes.
One example is the SWI/SNF complex, a general gene activator
complex that is required for the transcriptional induction of many genes in
yeast. It has a DNA-stimulated ATPase activity and is capable of relieving
nucleosome repression in an ATP-dependent manner [42]. Recently, the
SWI/SNF complex has been shown to be associated with the yeast RNA
polymerase II holoenzyme [43], providing strong support for its role as a
chromatin remodeling factor in either transcription initiation or elongation.
Another protein involved in nucleosome remodeling, the nucleosome
remodeling factor or NURF, which is distinct from the SWI/SNF complex, is
found in Drosophila. NURF is also capable of perturbing nucleosome
structure in the presence of ATP [44].
4. Transcription factor binding
A prerequisite for transcriptional activation is the binding of
transcription factors to their recognition sequences (reviewed in [45]). The
accessibility of the recognition sequences for transcription factors is restricted
in nucleosomes [3]. Depending on the mode of interaction between
transcription factors and their cognate DNA, some transcription factors can
recognize their binding sites within a nucleosome while others require a
nucleosome-free region to bind [46]. In the mouse mammary tumor virus
(MMTV) promoter, the glucocorticoid receptor (GR) is capable of binding to
the glucocorticoid response elements (GREs) located at the nucleosome dyad
facing away from the histone octamer. In contrast to GR, nuclear factor 1
(NF1) cannot bind to its recognition sequence within the core DNA of
nucleosomes (reviewed in [41]). The exclusion of NF1 from nucleosomes is
probably due to the binding mode of NF1 to its cognate DNA. NF1 requires
the whole circumference of the DNA for binding [47]. When DNA is
packaged into nucleosomes, the histone-DNA interaction occludes one side of
the DNA path on the histone surface, thereby causing steric hindrance for
NF1 binding [47]. Therefore, the model for glucocorticoid-induced gene
activation is that GR serves as the primary transcription factor capable of
binding to its target sequences within the nucleosome cores. The binding of
GR triggers nucleosome remodeling and allows the subsequent binding of
NF1 [41].
Although nucleosomes inhibit the binding of certain transcription
factors, not all promoter regions are entirely nucleosome-free. In fact, there
are several examples of nucleosome-mediated folding of regulatory DNA,
which results in a conformation that permits efficient interaction of the
transcription machinery [48].
The exact mechanism by which the above four characters of active
chromatin cooperate to allow or facilitate transcription has not yet been
completely defined. However, one of the more likely scenarios is as follows.
The binding of a primary transcription factor to its target sequence triggers
nucleosome remodeling. Associated with this process is the acetylation of
histones and loss of histone H1 from the nucleosome linker. The remodeled
nucleosome then allows secondary factors to associate with their recognition
sequences and to stimulate the assembly of the transcription initiation
complex, which subsequently leads to transcription (reviewed in [41, 49]).
In summary, the highly compact chromatin structure found in inactive
gene is perturbed in active genes. Active chromatin is characterized by
stretches of open, nucleosome-free regions bound by transcription factors.
Since the binding of transcription factors is so fundamental to chromatin
structure in active genes and it represents the next level of complexity beyond
the DNA helix, its effects on genotoxin target selection will be addressed in
my thesis study (Chapter 4).
F. The Human PGK1 As a Model Gene for Target Selection Studies
The X-linked phosphoglycerate kinase gene (PGK1) provides an
excellent opportunity to study the role of nucleosome structure, transcription
factor binding and DNA methylation on the selection of DNA targets by
genotoxins.
The PGK1 gene is a highly conserved housekeeping gene that codes for
phosphoglycerate kinase, an essential enzyme in glycolysis that catalyzes the
reversible conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate,
generating one molecule of ATP [50, 51]. In its inactive state, the human
PGK1 gene has two nucleosomes positioned in the promoter region, and
these nucleosomes are replaced by transcription factors in the
transcriptionally active copy of the gene (Figure 1.2). With regard to cytosine
methylation, the cytosines in the CpG dinucleotides are completely
methylated in the promoter region of the inactive PGK1 but unmethylated in
the active PGK1. Finally, the X-linked state of the PGK1 gene permits study of
both the inactive and active forms of the gene in human female cells. In the
following studies, I have made use of the human-hamster hybrid cell lines
containing either a single copy of an active human X chromosome (Y162-11C
cells) or an inactive X chromosome (X86T2 cells) [52]. The human X
chromosomes in these hybrid cells have been shown to maintain activity
states, methylation patterns, and protein-DNA footprints (i.e., the
experimental indicators of in vivo chromatin structure) very similar to
normal human lymphocytes [52, 53]. Thus, enediyne-mediated DNA damage
can be studied as a function of chromatin structure and DNA methylation in
the PGK1 model.
II. Enediynes As Model Genotoxins
My thesis research has focused on the enediyne family of antitumor
antibiotics, a structurally diverse family of DNA-cleaving molecules that
share a common mechanism for damaging DNA. The structural diversity
has allowed me to define the relationship between drug structure and
genomic target selection.
Enediynes are naturally occurring antitumor antibiotics isolated from
several eubacterial species (reviewed in [54]). The name of the family derives
from the common ene-diyne moiety in the core of these molecules that can
form carbon-centered radicals and abstract hydrogens from the DNA backbone
(Figure 1.3). Among the most studied members of the enediyne family are
calicheamicin [55], esperamicin [56, 57], neocarzinostatin [58, 59], C-1027 [60],
dynemicin [61], kedarcidin [62, 63], and maduropeptin [64] (for a review, see
[54, 65]). Enediynes are extremely potent cytotoxins that are lethal to tumor
cells at 10-9 to 10-15 M [66]. While this potency is credited to the ability of
enediynes to damage DNA, both from the in vitro DNA cleavage studies
(reviewed in [54, 65]) and the existence of DNA repair-deficient cell lines that
are hypersensitive to the compounds (e.g., [67]), relatively little is known
about the nature of enediyne DNA target(s) in vivo, or the roles of chromatin
structure and DNA methylation in the target selection process. These
questions form the basis of my thesis research.
Enediynes bind to DNA with high affinity and produce high levels of
double-stranded (DS) DNA damage by a common mechanism involving the
enediyne core structure. The affinity between enediynes and DNA has been
estimated to range over 106-10- M, depending on the sequences of DNA used
in the studies [58, 68]. The DNA damage mechanism of the enediyne core in
calicheamicin and esperamicin is shown in Figure 1.4. Initiated by a
nucleophilic attack at the methyltrisulfide trigger by thiols (presumably
glutathione in vivo), the enediyne core undergoes a Bergman-Masamune
rearrangement to form a diradical intermediate [69]. When the drug binds in
the minor groove of DNA, the diradical abstracts hydrogen atoms from
deoxyribose of both strands. Deoxyribose lesions then undergo oxygen-
dependent reactions, yielding a spectrum of degradation products unique to
each abstracted hydrogen. The final degradation products include strand
breaks with 5'- and 3'-phosphates, 3'-phosphoglycerate, and modified abasic
sites (Figure 1.5) [58, 65]. Calicheamicin produces DS lesions exclusively, with
the lesions consisting of either two direct breaks or an abasic site opposite a
single-strand (SS) break (Figure 1.6, left panel) [70, 71]. DNA damage by the
parent esperamicin, esperamicin Al, consists of both SS breaks (75%) and DS
lesions (25%) with an abasic site opposite a strand break (Figure 1.6, right
panel) [71]. Esperamicin C, the analog of esperamicin Al missing the
anthranilate-deoxyfucose moiety (Figure 1.7), produces mostly DS lesions
(>95%) like calicheamicin (Figure 1.6, left panel). In all cases, polyamines (e.g.,
putrescine) and lysines (either free or on nucleoproteins) cleave the abasic
sites and nucleoside aldehydes, leaving ~85% of the ends of the DS breaks
with both 3'- and 5'-phosphates and 3'-three nucleotide overhang (3-nt 3'-
overhang) (Figure 1.6, middle panel) [72-74]. These drug-specific DNA ends
will be exploited throughout my studies for the mapping of enediyne-specific
DNA damage in the genome.
In spite of this common mechanism for damaging DNA, the enediynes
differ significantly in the structure and arrangement of functional groups
attached to the enediyne core (Figure 1.3). In my thesis research, I have
focused on calicheamicin and esperamicins, which include esperamicin Al
and esperamicin C (Figure 1.7). Calicheamicin and esperamicin have an
identical aglycone core, the bicyclic ring that contains the enediyne moiety.
However, the terminal carbohydrate-aromatic group in calicheamicin is
positioned on the opposite side of the enediyne core in esperamicin Al, in the
form of an anthranilate-deoxyfucose moiety (Figure 1.7). This anthranilate-
deoxyfucose group is missing in esperamicin C. In my studies, I have used
these structural differences to define the role of various enediyne structural
motifs in the selection of cellular DNA targets in vivo.
III. Earlier Studies of Enediyne Target Selection In Vitro
The aim of my thesis research is to explore enediyne target selection in
the complex milieu of the whole cell, and to test the relevance of in vitro
models of enediyne target selection.
Previous studies in this laboratory have established models by which
enediynes select their DNA targets in naked DNA and chromatin in vitro.
This is illustrated by our studies of calicheamicin and esperamicins Al and C.
Using isolated nuclei and nucleosome core particles, Yu et al. demonstrated
that these drugs target different regions of isolated nucleosomes [28].
Esperamicin Al was limited to damaging the linker DNA that joins adjacent
nucleosome cores, a behavior similar to that of an intercalating agent. It was
subsequently shown that the anthranilate of esperamicin Al was a novel
DNA intercalator [71, 75].
However, calicheamicin and esperamicin C, an esperamicin Al analog
missing the sugar-anthranilate moiety, cleave both the linker and core DNA
[28]. The aromatic ring in the side chain of calicheamicin did not intercalate
in DNA and calicheamicin was capable of binding to DNA when the minor
groove faced away from the nucleosome core [76]. Further studies in
reconstituted nucleosomes revealed that calicheamicin damage at one site in
the nucleosome occurred 4-fold more frequently than in naked DNA [76].
This finding suggested that there may be sites in the nucleus where protein-
DNA complexes create high affinity targets for calicheamicin and other DNA-
damaging agents.
Two observations led to the proposal that calicheamicin targets curved
or flexible DNA sequences. First was the ability of calicheamicin to bind to
the bent region of nucleosome core DNA. Second, we and others have also
observed that calicheamicin produces damage mainly at the 3'-ends of purine
runs [76, 77]. One explanation for this behavior is that calicheamicin targets
an unusual structure at the 3'-end of a purine tract, such as a kink or hinge at
the purine/pyrimidine junction. This hypothesis is supported by the studies
of Salzberg et al., who found that calicheamicin bends DNA upon binding
and that the binding sites may be flexible DNA sequences [78]. It is thus
possible that calicheamicin will target curved or flexible DNA in certain
regions of the chromatin in vivo.
In my thesis research, I have tested the relevance of these in vitro
observations in the setting of the whole cell. Using the human PGK1 as a
model gene, I have studied the effects of positioned nucleosomes (Chapter 3)
and transcription factors (Chapter 4) on enediyne target selection in vivo.
IV. Significance
The research presented in this study is significant for several reasons.
First, I have carried our earlier studies in naked DNA and reconstituted
nucleosomes into the nucleus of a living cell. This allowed us to test the
relevance of DNA target recognition established in these in vitro models.
Secondly, the structural diversity of the enediynes provides an opportunity to
define the roles of the various enediyne structural elements in target
selection in vivo. Third, the techniques developed and the results obtained
with enediynes will be broadly applicable to understanding the target
selection mechanisms of other genotoxins. Finally, the knowledge gained
from these studies will provide important information for the design of
targeted anticancer drugs and for understanding the mechanism of
genotoxin-induced mutagenesis.
V. Figures for chapter one
Figure 1.1. Multiple factors of DNA structure in the mammalian nuclei may
interact collectively with genotoxin structure to determine genotoxin target
selection in vivo.
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Figure 1.2. Chromatin structures of the human X chromosome-linked
phosphoglycerate kinase gene (PGK1). The positions of nucleosomes in the
inactive PGK1 and transcription factors in the active PGK1 were derived from
the in vivo DNase I footprinting studies of Pfeifer and coworkers [79, 80].
The X chromosome location of PGK1 allows a comparison of DNA damage in
the same gene in different states of chromatin structure.
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Figure 1.3. Members of the enediyne family. Enediynes are naturally
occurring antitumor antibiotics isolated from several eubacterial species
(reviewed in [54]). The name of the family derives from the common ene-
diyne moiety in the core of these molecules that can form carbon-centered
radicals and abstract hydrogens from DNA backbones.
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Figure 1.4. DNA damage mechanism of the enediyne core in calicheamicin
and esperamicin. Initiated by a nucleophilic attack at the methyltrisulfide
trigger by thiols (presumably glutathione in vivo), the enediyne core
undergoes a Bergman-Masamune rearrangement to form a diradical species.
When the drug binds in the minor groove of DNA, the diradical abstracts
hydrogen atoms from deoxyribose of both strands to cause DNA lesions. The
drug is deactivated after hydrogen abstraction [69].
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Figure 1.5. The expression of DNA lesions after hydrogen abstraction by
enediynes. Enediynes can abstract hydrogens protrude toward the minor
groove of a duplex DNA, which are the 1', 4', and 5' hydrogens. Deoxyribose
lesions then undergo oxygen-dependent reactions, yielding a spectrum of
degradation products unique to each abstracted hydrogen [58, 65].
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Figure 1.6. DNA lesions produced by calicheamicin, esperamicin Al and C.
Calicheamicin produces DS lesions exclusively, with the lesions consisting of
either two direct strand breaks or an abasic site opposite a single-strand (SS)
break (left panel) [70, 71]. DNA damage by the parent esperamicin,
esperamicin Al, consists of both SS breaks (75%) and DS lesions (25%) with an
abasic site opposite a strand break (right panel) [71]. Esperamicin C, the analog
of esperamicin Al missing the anthranilate-deoxyfucose moiety, produces
mostly DS lesions (>95%) like calicheamicin (left panel). In all cases,
polyamines (e.g., putrescine) and lysines (either free or on nucleoproteins)
cleave the abasic sites and nucleoside aldehydes, leaving -85% of the ends of
the DS breaks with 3 nucleotide (3-nt) 3'-overhangs opposite 5'-phosphates
(middle panel) [72-74].
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Figure 1.7. Members of the enediyne family used in my thesis study.
Calicheamicin and esperamicin have an identical aglycone core, the bicyclic
ring that contains the enediyne moiety. However, the terminal carbohydrate-
aromatic group in calicheamicin is positioned on the opposite side of the
enediyne core in esperamicin Al, in the form of an anthranilate-deoxyfucose
moiety. This anthranilate-deoxyfucose group, which is an DNA intercalator
[71], is missing in esperamicin C. This structural diversity allows one to
define the relationship between drug structure and target selection.
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CHAPTER 2
DEVELOPMENT OF A MODIFIED LIGATION-
MEDIATED PCR STRATEGY TO MAP ENEDIYNE-
SPECIFIC DNA DAMAGE
I. Introduction
In Chapter two, a modified ligation-mediated polymerase chain
reaction (LMPCR) is described that can accommodate the structure of
enediyne-induced double-strand breaks. This technique, along with the
conventional LMPCR, is used to identify the DNA damage distributions
along the human PGK1 gene and the factors that modulate damage
distribution (Chapters 3-5).
To define the location and relative quantity of drug-induced damage in
the single-copy PGK1 gene, I needed a very sensitive method for mapping
DNA damage. Traditionally, Southern-blot has been used to measure the
extent of DNA damage in specific DNA sequences in cells (reviewed in [81]).
However, due to its limited sensitivity, only damage in multi-copy sequences
could be studied and resolution was limited to hundreds of base pairs [81].
LMPCR, on the other hand, allows the mapping of DNA damage at
single nucleotide resolution in single-copy genes [82-84]. This technique was
initially developed to address a problem that limits the use of PCR in
genomic footprinting and sequencing studies: only one end of a DNA
sequence is defined when strand breaks are introduced along the sequence.
LMPCR solves the problem by ligation of a second defined sequence at sites of
strand breaks [85, 86].
The technique of LMPCR is illustrated in Figure 2.1. Cells or purified
DNA are first treated with a DNA damaging agent and DNA lesions or
adducts are converted to strand breaks with 5'-phosphate ends compatible
with DNA ligase. In the "first-strand synthesis", a gene-specific primer is
annealed to the purified DNA and extended with a DNA polymerase until it
reaches a strand break to create a blunt-ended DNA fragment. A duplex
oligonucleotide linker is then ligated to the blunt-ended fragments. This
creates a substrate suitable for PCR and allows for the simultaneous
amplification of all blunt-ended DNA fragments, using a primer
complementary to the linker sequence and a second gene-specific primer.
After amplification, the resulting damage ladder will be uniformly longer due
to the length of the added linker. However, the Maxam-Gilbert sequencing
standards [87] will also be amplified by the same procedure. Thus, the
locations of genotoxin-induced damage sites are determined relative to the
sequencing standards on a sequencing gel. All damage and sequence ladders
can be visualized by extension of a [32P]-labeled gene-specific primer (Figure
2.1). Alternatively, the damage sites can be identified by blotting and
hybridization with a radio-labeled gene-specific probe. The frequency of DNA
damage at each site is determined by phosphorimager analysis.
I have modified the conventional LMPCR method to make it more
specific for enediyne-induced DNA damage. As shown in Figure 2.2 (middle
panel), after putrescine (a polyamine) treatment, calicheamicin and
esperamicin produce double strand breaks with 5'-phosphates and three
nucleotide 3'-overhangs (3-nt 3'-overhangs). Drug-induced double strand
breaks can be directly ligated to oligonucleotide linkers with a randomized 3-
nt 3'-overhang that complements the drug-induced overhangs (Figure 2.3).
The advantage of this approach is that it circumvents the need for first-strand
synthesis. In addition, direct ligation of the double-strand linker prevents any
background single-strand nicks from being ligated and amplified, thus
making the technique more specific for drug-induced DNA damage. The
technique is also applicable to the 2-nt overhangs produced by other
enediynes (e.g., C-1027 [60, 88]), as long as the end of the randomized linkers
are changed accordingly.
II. Materials and Methods
Sources of the enediynes. Calicheamicin was kindly provided by Dr. G.
Ellestad, Wyeth-Ayerst Research; esperamicin Al and C were kindly
provided by Dr. J. Golik, Bristol-Myers Squibb.
Cell culture. HeLa S3 cells were grown as a suspension culture in
Joklik modified Eagle's minimum essential medium with 10% newborn
calicheamicin serum (Sigma) and 1% penicillin/streptomycin (Sigma).
Human-hamster hybrid cell lines containing either an inactive human X
chromosome (X8/6T2 cells) or an active human X chromosome (Y162/11C
cells) were kind gifts of Dr. S. Gartler, Univ. Washington, Seattle. They were
grown as a monolayer in RPMI 1640 medium with 10% fetal calicheamicin
serum (Sigma) and 40 gg/ml Gentamicin (Sigma) [52].
Treating cells with enediynes. Cells are harvested at -80% confluency
and resuspended in phosphate-buffered saline (PBS) at 107 cells/ml. An
aliquot of calicheamicin or esperamicin in methanol was added (final
methanol concentration <1%), and the reaction was allowed to proceed for 30
min at 370C. This incubation time was long enough to ensure that DNA
damage was virtually complete, yet short enough to avoid significant repair
or apoptosis [28]. We have previously demonstrated that enediyne-mediated
DNA damage in nuclei was a direct result of the drug, and was not mediated
by topoisomerases or nucleases [28]. The drug-damaged DNA was purified
using a QiaAmp blood kit (Qiagen) and then treated with 100 mM putrescine
for 1 hr at 370C to cleave abasic sites to strand breaks with phosphate-ends [69,
89, 90]. DNA samples were finally ethanol precipitated and redissolved in 1
mM Tris, 0.1 mM EDTA (pH 7.8) at 1 mg/ml.
Treating purified DNA with enediynes. Genomic DNA was purified
using a QiaAmp blood kit and dissolved in 50 mM HEPES, 5 mM EDTA, 10
mM glutathione (pH 7.0) at 0.1 mg/ml. An aliquot of calicheamicin or
esperamicin in methanol was added (final methanol concentration <1%), and
the reaction was allowed for 30 min at 370C. The drug-damaged DNA was
treated with putrescine as described above. DNA samples were then ethanol
precipitated and redissolved in 1 mM Tris, 0.1 mM EDTA (pH 7.8) at 1 mg/ml.
Maxam-Gilbert reactions. DNA sequence ladders generated by base-
specific DNA cleavage and conventional LMPCR are essential for the precise
mapping of damage distribution at single-nucleotide resolutions. For
Maxam-Gilbert sequencing reactions [87], purified genomic DNA was
concentrated by ethanol precipitation to 5-10 mg/ml. The reactions were
performed according to a protocol optimized for LMPCR [91].
Oligonucleotide sequences. Gene-specific primers #1 and #2 for the
PGK1 promoter region were identical to that of Pfeifer et al. [53]. Labeling
primers #3 was chosen to meet the criteria established by Mueller and Wold
[92], and designed with the aid of Primer 0.5 software [93] using 50 mM salt
concentration and 0.25 nM DNA concentration [94]. An upstream primer set
A and a downstream primer set B were used. Each primer set consisted of
three primers: primer Al (first strand synthesis): AAGTCGGGAAGGTTCCTT;
primer A2 (PCR amplification): AAGGTTCCTTGCGGTTCGCGGCG; primer
A3 (labeling): AAGGTTCCTTGCGGTTCGCGGCGTG. Primer BI (first strand
synthesis): CGTCCAGCTTGTCCAGC; primer B2 (PCR): TCCAGCGTCAGCT
TGTTAGAAAGCG; primer B3 (labeling): TTCAGCGTCAGCTTGTTAGAA
AGCGAC. The positions of these primers along the promoter region of PGK1
gene were shown in Figure 2.4. The sequence of the linker primer was as
described elsewhere [85].
For conventional LMPCR, the linker consisted of a 25-mer annealed to
an 11-mer [85, 86]. For modified LMPCR, the long strand of the linker
contained a randomized 3-nt 3'-overhang (Figure 2.3). Randomization of the
three terminal nucleotides of the 28-mer was achieved using an equimolar
mixture of all four nucleotides during synthesis (Oligos Etc). The resulting
linker thus contained equal amounts of all 64 permutations of 3-nt 3'-
overhangs, allowing it to accommodate all possible sequences damaged by
calicheamicin and esperamicins.
Conventional LMPCR. To ensure the quantitative nature and
reproducibility of the LMPCR process, all samples in each experiment were
prepared in parallel. Master reaction cocktails were used to minimize
pipetting error.
Conventional LMPCR was performed on drug-treated samples and
Maxam-Gilbert sequencing markers. The protocol was a hybrid of Pfeifer's
and Mueller's protocols [92, 95]. First strand synthesis: 2 jig of DNA, 0.6
pmoles of primer 1, 3 1l of 5x Sequenase buffer (250 mM NaCl, 200 mM Tris-
HCI pH 7.7), and sufficient water were mixed in a final volume of 15 Cl. The
DNA was denatured at 950C for 3 min and primer annealing was allowed to
occur at 480C for 30 min. The sample was then chilled on ice and spun briefly
in a microcentrifuge. To the annealed sample, 7.5 p1 of freshly prepared Mg-
dNTP solution (made by mixing 47 L1 of water, 1 Al of 1 M MgC2, 1 Al of I M
DTT, and 1 p1 of 25 mM dNTP) and 1.5 Cl of Sequenase at 3.25 units/pl [made
by diluting stock Sequenase 2.0 (13 units/ml, (United States Biochemical-
Pharmacia) four-fold in ice cold TE pH 8.0) were added. The following
temperature ramp was applied to the sample in a thermocycler (MJ Research):
480C for 5 min, 500 C for 1 min, 510C for 1 min, 520C for 1 min, 540C for 1 min,
560 C for 1 min, 580C for 1 min, and 600 C for 1 min. This temperature ramp
during the first strand synthesis step was found to minimize PCR background
[96]. The sample was cooled on ice and 6 L1 of 300 mM Tris-HCI pH 7.7 was
added. The sample was finally heat inactivated at 670C for 15 min, cooled on
ice and spun briefly.
Linker ligation and PCR amplification were performed according to
Pfeifer et al. [95, 97]. Briefly, 45 .1 of freshly prepared ligation mix (13.33 mM
MgC12, 30 mM DTT, 1.66 mM ATP, 83 mg/ml bovine serum albumin, 3 units
per reaction T4 DNA ligase (Promega), and 100 pmoles linker) was added to
the above sample. Ligation was allowed to occur at 180C for 16 hours, and
terminated by heating to 700C for 10 min. DNA was precipitated by ethanol,
dried under vacuum, and dissolved in 50 p. of water. A 50 .1 aliquot of
freshly prepared master Taq polymerase mix was added to each sample. This
polymerase mix consisted of 20 mM Tris-HC1 (pH 8.9), 80 mM NaCl, 0.02%
gelatin, 4 mM MgC12, 0.4 mM of each dNTP, 10 pmoles of primer #2, 10
pmoles of linker-primer, and 3 units of Taq polymerase (Boehringer-
Mannheim). PCR (20 cycles) was performed on a thermocycler using the
following temperature profile: 950 C for 1 min, 670 C for 2 min, 760 C for 3 min;
with an additional 7 min of 760 C in the last cycle.
After PCR, samples were transferred to ice and 5 .1 of the following
labeling mix was added per reaction: mix 1 .l of 5x Taq buffer (200 mM NaC1,
50 mM Tris-HCl pH 8.9, 0.05 % (w/v) gelatin), 2.5 pmoles of the 5'-[32P] end-
labeled primer #3, 6.25 nmoles of each dNTP, 1.5 units of Taq polymerase, and
sufficient water to bring the volume to 5 .l. PCR products were then labeled
by 2-4 repetitions of the following thermocycler program: 950C for 1 min, 690C
for 2 min, and 760 C for 10 min [92].
Note: In certain cases, background smearing posed a problem in this direct
labeling strategy. A gel transfer and hybridization method was used to
eliminate the problem (see Chapter 3 and [91, 97, 98]).
Modified LMPCR. Enediyne-treated DNA samples were also subjected
to an alternative LMPCR strategy, which exploited the unique three
nucleotide 3'-overhangs present on all double-strand breaks produced by
calicheamicin and esperamicins Al and C [70, 71].
Drug-damaged DNA was ligated directly to a modified linker
possessing a three nucleotide 3'-overhang complementary to the drug-
induced overhang. The modified linker consisted of a 28-mer
oligonucleotide (GCGGTGACCCGGGAGATCTGAATTCNNN, where N
represents a randomized nucleotide) annealed to an 11-mer oligonucleotide
(5'-GAATTCAGATC) at 20 pmoles/pl. Randomization of the three terminal
nucleotides of the 28-mer was achieved using an equimolar mixture of all
four nucleotides during synthesis (Oligos Etc.). The resulting population of
oligonucleotides provided complementary 3'-overhangs for all possible
damage sites (Figure 2.3). The use of the modified linker obviated the need
for first-strand synthesis. Ligation reactions consisted of 2 gg of DNA, 7.5 Cl of
10x ligase buffer (Promega), 1 pl of ligase (Promega, 3 units/pl), 100 pmoles of
modified-linker, and sufficient water to yield a 75 Cl final volume. Ligation
was allowed to occur at 180C for 16 hours. The PCR amplification and labeling
steps were the same as the conventional LMPCR described above.
Sequencing gel analysis. All LMPCR samples were phenol/chloroform
extracted, ethanol precipitated, and resuspended in 4 pl formamide loading
buffer (95% v/v formamide, 20 mM EDTA pH 8.0, 0.05% xylene cyanol, 0.05%
bromophenol blue). Half of each sample (2 pl) was loaded onto an 8%
polyacrylamide gel. Electrophoresis was carried out at 80 watts constant
power (~50°C gel temperature) for 2 to 6 hours. Gel was dried under vacuum
and exposed to a phosphor image screen over night. The image was scanned
by a PhosphorImager (Molecular Dynamics).
III. Results and Discussion
Comparison of conventional LMPCR and modified LMPCR. It was
hypothesized that the modified LMPCR would make the technique more
specific for enediyne-induced DNA damage by reducing the amplification of
background single-strand nicks, due to the specificity of the modified linker
for enediyne-induced DNA breaks. This hypothesis was tested with
calicheamicin, an enediyne that produces double strand breaks exclusively
[70]. As shown in Figure 2.5, modified LMPCR produced less background and
cleaner signals than did conventional LMPCR, resulting in a more
distinguishable signal at 100 nM calicheamicin concentration (lane 8 vs. lane
3).
Also shown in Figure 2.5 are the results of amplifying Bsl I-digested
DNA by modified (lane 13) and conventional LMPCR (lane 14). Bsl I
produces a 3-nt 3'-overhang that is compatible with the modified linker.
Notice that in both Bsl I-digested and calicheamicin-damaged DNA, the
products from the modified LMPCR are 3 bases longer than those from the
conventional LMPCR. This is because the long strand of the mixed-linker is 3
nucleotides longer than the conventional linker, due to its 3-nt overhang
(Figure 2.3). This should be kept in mind when determining the location of
enediyne-mediated DNA damage by modified LMPCR.
Taking into account the 3-nt size difference and the gain of signal-to-
background ratio in the modified LMPCR, most of the major DNA damage
sites detected by the conventional LMPCR was also detected by the modified
LMPCR. This indicates the validity of modified LMPCR in mapping
enediyne-induced DNA damage.
Single-hit conditions are important when mapping DNA damage sites
by LMPCR. In LMPCR, it is important to work under conditions in which the
gene region of interest is damaged only once. Multiple lesions in the
amplified region will cause a bias toward shorter DNA fragments since only
break sites closest to the gene-specific primer will be amplified. Figure 2.5 also
shows that single-hit conditions are important for the quantitative
comparison of damage frequency along DNA sequences. Good dose-response
was obtained with modified LMPCR from 10 nM to 1 gM calicheamicin
concentrations (lanes 7 to 9). However, when calicheamicin was used at 10
gIM (lane 10), multiple damage sites in the region of interest bias the LMPCR
toward shorter fragments.
To ensure that drug damage is within single-hit conditions in the DNA
region of interest, the size of DNA fragments in the drug-treated sample is
assessed by agarose gel electrophoresis. The molecular weight corresponding
to the mobility of the peak mass distribution should be 6000 bp or greater.
This ensures that greater than 99% of the DNA substrate receives less than or
equal to one hit within a 400 bp region starting from the gene-specific primer
(see appendix for mathematical derivations). In practice, the peak mass
distribution of 6000 bp or greater is readily achieved by treating purified DNA
with 1 jgM concentration or lower and by treating whole cells with 20 jtM or
lower drug concentrations.
The quantitative nature of LMPCR. Although PCR is an exponential
process, the amount of PCR product is linearly proportional to the number of
template molecules, as long as the following two conditions are satisfied.
First, all reaction components except template must be in vast excess, as is
usually the case for at least the first 20 cycles [99]. Second, statistical sampling
errors must be minimized by starting with at least 100 molecules of each
template fragment [84]. This is readily achieved by starting with 2 Pig of DNA
(-6x105 copies of the genome; [100]) damaged to an average fragment size of
6000 bp. This damage frequency ensures single-hit conditions within the 400
bp region analyzed by any gene-specific primer (see above), and ensures that
there are at least 100 molecules of each damage site fragment (see appendix for
mathematical derivations).
The quantitative nature of the LMPCR is shown in Figure 2.6, in which
HeLa genomic DNA was cleaved with Ras I. In lanes 1 and 3, 1 or 2 gg of
digested DNA was amplified by LMPCR, respectively, using primers specific
to the PGK1 promoter. LMPCR signals in these lanes indicated fragments of
the expected size, and the signals were quantitated using the ImageQuant
software. The signal intensities in lanes 1 and 3 were 1729 and 3587 counts,
respectively; non-digested controls showed very little background. Thus, two-
fold differences in the amount of the starting material can be detected. Pfeifer
et al. also reported that the two-fold differences between one X chromosome-
containing male DNA and two X chromosome-containing female DNA could
be reliably detected [53, 80].
LMPCR is also highly reproducible. The last two lanes in Figure 2.5
(lanes 15-16) are both T+C reaction markers, amplified with primer annealing
temperatures of 690C and 670C, respectively. The results are
indistinguishable. Thus, LMPCR is a robust technique and slight differences
in amplification conditions still yield the same results.
In conclusion, a reliable and quantitative LMPCR procedure was
established. This allowed mapping of enediyne-induced DNA damage in any
DNA region where primer sequences were known. In subsequent Chapters, I
will apply the conventional and modified LMPCR to the human PGK1 gene
model to study the roles of nucleosomes, transcription factors, and DNA
methylation in the selection of DNA targets by enediynes.
IV. Figures for chapter two
Figure 2.1. Schematic comparison of the conventional and modified LMPCR.
See main text for a detailed description.
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Figure 2.2. DNA lesions produced by calicheamicin, esperamicin Al and C.
Calicheamicin produces DS lesions exclusively, with the lesions consisting of
either two direct strand breaks or an abasic site opposite a single-strand (SS)
break (left panel) [70, 71]. DNA damage by the parent esperamicin,
esperamicin Al, consists of both SS breaks (75%) and DS lesions (25%) with an
abasic site opposite a strand break (right panel) [71]. Esperamicin C, the analog
of esperamicin Al missing the anthranilate-deoxyfucose moiety, produces
mostly DS lesions (>95%) like calicheamicin (left panel). In all cases,
polyamines (e.g., putrescine) and lysines (either free or on nucleoproteins)
cleave the abasic sites and nucleoside aldehydes, leaving -85% of the ends of
the DS breaks with 3 nucleotide (3-nt) 3'-overhangs opposite 5'-phosphates
(middle panel) [72-74].
Calicheamicin and Esperamicin C Polyamines and lysine cleave Esperamicin Al
abasic sites and nucleoside aldehydes
Figure 2.2
Figure 2.3. Structure of the modified and conventional linkers. The long
strand of the modified linker is three nucleotides longer than the
conventional linker, due to the randomized 3-nt 3'-overhang. The
nucleotide randomization was created by using an equimolar mixture of all
four nucleotides during synthesis. The resulting linker thus contains equal
amounts of all 64 permutations of 3-nt 3'-overhangs, allowing it to
accommodate all possible sequences damaged by calicheamicin and
esperamicins.
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Figure 2.4. The position of primer set A and B on the human PGK1 gene.
Each primer set consists of three primers for first strand synthesis (primer 1),
PCR amplification (primer 2), and labeling (primer 3).
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Figure 2.5. Results of conventional and modified LMPCR. Lanes 1-5 were
conventional LMPCR amplification of HeLa DNA damaged by 0, 10 nM, 100
nM, 1 lpM, and 10 M of calicheamicin, respectively. Lanes 6-10 were
modified LMPCR amplification of HeLa DNA damaged by 0, 10 nM, 100 nM, 1
p.M, and 10 pM of calicheamicin, respectively. Lanes 11 and 12 are GA- and
TC-specific reactions amplified by conventional LMPCR. Lanes 13 and 14 are
Bsl I-digested DNA amplified by modified and conventional LMPCR,
respectively. Bsl I produces 3-nt 3'-overhangs that are also ligatable by the
modified linker. Notice that the product from the modified LMPCR is 3 bases
longer than that from the conventional LMPCR, as expected. Lanes 15 and 16
are both TC-specific reactions amplified at 69 and 670 C, respectively.
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Figure 2.6. The quantitative nature of LMPCR. Lanes 1 and 3 are modified
LMPCR amplification of different amounts of Rsa I digested HeLa DNA: 1 and
2 gg, respectively. Lanes 2 and 4 are modified LMPCR amplification of
undigested HeLa DNA: 1 and 2 gg, respectively. The LMPCR bands in lanes 1
and 3 are at the expected size (pointed by the arrow), and are subjected to
volume quantitation by the ImageQuant software: bands A and B has 1729
and 3587 counts, respectively. Blunt linkers were used to ligate directly to Rsa
I-induced blunt ends in these experiments.
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CHAPTER 3
THE ROLE OF NUCLEOSOMES
IN ENEDIYNE TARGET SELECTION
I. Introduction
The packaging of DNA as chromatin in cells alters both its
conformation and dynamics (Chapter 1). These perturbations introduce
another level of complexity to the mechanisms by which DNA-damaging
chemicals select their targets. To better understand how genomic
organization affects target selection by genotoxins, I have compared the DNA
damage produced by two enediynes, calicheamicin and esperamicin, in a
single-copy human gene. In this Chapter, I will focus on the effects of
nucleosome structure in the inactive human PGK1 gene on enediyne target
selection in vivo.
The nucleosome is a basic element of chromatin structure [3] as well as
a model for the effects of protein binding on DNA structure and dynamics
(Chapter 1). It consists of two regions, core and linker. The core is composed
of ~146 base pairs of DNA wrapped -1.8 times in a left-handed superhelix
around four pairs of histone proteins, and the linker represents the 20-60 base
pairs of DNA joining adjacent cores [3, 4]. In addition to the bending-induced
changes in DNA structure, the nucleosomal DNA is constrained in its
dynamics by protein-DNA contacts. This constraint contributes to the
reduced binding of intercalating agents to nucleosome core DNA [29-32].
The enediyne family of antitumor antibiotics presents a unique
opportunity to study the relationship between drug structure and selection of
DNA targets in chromatin. Calicheamicin and esperamicins share a common
mechanism for producing DNA damage, yet differ in the organization of
functional groups attached to the enediyne core (Chapter 1). Specifically, the
terminal carbohydrate-aromatic group of the calicheamicin tetrasaccharide
side chain is positioned on the opposite side of the enediyne core in
esperamicin Al, in the form of a deoxyfucose-anthranilate moiety. This
group is missing in esperamicin C (Figure 1.7).
The diversity of enediyne structure suggested that the drugs would
target different regions of chromatin in cells, an hypothesis supported by our
studies in isolated chromatin [28] and reconstituted nucleosomes [76, 101].
These studies revealed that esperamicin Al was limited to damaging the
linker region between nucleosome cores due to intercalation of an
anthranilate moiety [71]. However, calicheamicin and esperamicin C, which
are nonintercalating groove-binders, damaged both the core and linker DNA
[28, 76, 101]; core DNA damage in this case was limited to sites where the
minor groove faced away from the histone proteins. These observations
serve as a model for the relationship between enediyne structure and in vivo
target selection, and they suggest that the structural diversity of the enediynes
can be exploited to probe chromatin structure in cells.
To test the validity of these in vitro models, I have now examined
enediyne-induced damage in a single copy gene in living cells. Using
LMPCR, I demonstrate that esperamicin Al-induced DNA damage is
suppressed in two putative nucleosome cores in the transcriptionally silent
human PGK1 gene, while calicheamicin and esperamicin C produced damage
throughout the nucleosome. These results confirm hypotheses generated
from studies about enediyne target selection in isolated chromatin and
reconstituted nucleosomes, and suggest that enediynes may prove useful as
chromatin footprinting agents.
II. Materials and Methods
Materials and cell lines. Calicheamicin ylI and esperamicin Al and C
were provided by Dr. George Ellestad (Wyeth-Ayerst Research) and Dr. Jerzy
Golik (Bristol-Myers Squibb), respectively. Chinese hamster-human hybrids
containing either an inactive (cell line X86T2) were provided by Dr. Stanley
Gartler (University of Washington, Seattle; ref. [52]. A clone of X86T2 cells
enriched in the human X chromosome was provided by Dr. Gerd Pfeifer (City
of Hope Medical Center, Duarte, CA). Cells were grown as a monolayer in
RPMI 1640 with 10% fetal calicheamicin serum and 40 gg/ml Gentamicin [52].
A clone of the upstream region of the human PGK1 gene, pBSHPGK1, was
provided by Dr. Judith Singer-Sam (City of Hope Medical Center, Duarte, CA;
[102].
Treatment of cells with enediynes. Cells were harvested at -80%
confluency and resuspended in phosphate-buffered saline (PBS) at 107
cells/ml. Drug treatment, DNA purification, and putrescine treatment were
as described before (Chapter 2). DNA samples were finally ethanol
precipitated and redissolved in 1 mM Tris, 0.1 mM EDTA (pH 7.8) at 1 mg/ml.
Treatment of purified DNA with enediynes. Genomic DNA was
purified using a QiaAmp blood kit and dissolved in 50 mM HEPES, 5 mM
EDTA, 10 mM glutathione (pH 7.0) at 0.1 mg/ml. Drug treatment, putrescine
treatment, and DNA purification were as described before (Chapter 2). After
ethanol precipitation, DNA samples were dissolved in 1 mM Tris, 0.1 mM
EDTA (pH 7.8) at 1 mg/ml.
For DNA sequencing reactions, purified genomic DNA was
concentrated by ethanol precipitation to 5-10 mg/ml. Maxam-Gilbert
sequencing reactions were performed according to an LMPCR-optimized
protocol [91].
LMPCR. We employed two LMPCR techniques that used the following
primers in the 5' region of the human PGK1 gene: CGTCCAGCTTGTCCAGC
(+134 to +118, primer 1); TCCAGCGTCAGCTTGTTAGAAAGCG (+123 to +99,
primer 2); TGGGGAGAGAGGTCGGTGATTCGGTCA (+80 to +54, primer 3);
TCCAGCGTCAGCTrGTTAGAAAGCGACAT (+123 to +95, primer 4). The
sequences of the blunt linker and linker primer were as described elsewhere
[85]. Conventional LMPCR was performed as described in Chapter 2. Half of
each sample was resolved on a 6% sequencing gel. Electroblotting and
hybridization were performed as described elsewhere [95]. The hybridization
probe was made by repeated primer extension from a cloned PGK1 template
(pBSHPGK1) using primer 3 and Taq polymerase [103]. Hybridized
membranes were subjected to phosphorimager analysis (Molecular
Dynamics).
Modified LMPCR was also performed as described in Chapter 2. After
20 cycles of amplification, labeling mix was added and each sample was
subjected to 4 cycles of labeling (Chapter 2). Half of each sample was resolved
on a 4-6% sequencing gel, which was then dried and subjected to
phosphorimager analysis (Molecular Dynamics).
Data analysis. In order to compare damage frequency in isolated and
cellular DNA, I performed the experiments with drug concentrations that
produced roughly similar levels of DNA damage in the two situations. This
amounts to roughly a 10-fold higher concentration of drug for treating cells
than isolated DNA (e.g., Figure 3.1). The difference is likely due to factors
such as accessibility of DNA in higher order chromatin structures,
sequestration of the drug in lipid membranes in the cells, or deactivation of
the drugs in the cytoplasm.
I then accounted for unavoidable differences in the levels of DNA
damage in different DNA samples and for lane-to-lane variation in gel
loading. To do this, I normalized the phosphorimager signal intensities in
each lane so that damage in putative nucleosome linker regions was the same
in both isolated and cellular DNA. For example, the signal intensities for
damage produced by esperamicin Al in cellular DNA (Figure 3.1, lane 5) were
multiplied by a factor of three so that damage frequencies in the region -+20
to -+70 were the same in both naked and cellular DNA. In this case, the
factor of three represents the average difference in signal intensity for four
major peaks in this region in isolated and cellular DNA (see Figure 3.2).
The validity of the normalization process is illustrated by three points.
First, the expectation of equivalent amounts of damage in the nucleosome
linkers has firm foundations in our previous in vitro studies [28, 76].
Second, normalization of the data to the linker peaks is used consistently in
all of our studies to avoid any biases. Finally, normalization of the data to
either of the two linker regions in the inactive PGK1 gene, (i.e., +20 to +70
and around position -200 in Figure 3.2A) produces the same result.
III. Results
Mapping esperamicin-induced DNA damage in the PGK1 gene by
modified LMPCR. In this experiment, a modified linker was ligated directly
to the double-strand breaks produced by esperamicins Al and C. It should be
noted that single-strand breaks produced by esperamicin Al would not be
detected using the modified linker.
The damage produced by esperamicins Al and C in naked DNA and in
cells containing an inactive PGK1 is shown in the gel in Figure 3.1 and in the
line graphs in Figure 3.2. Examination of Figure 3.1 reveals that 10- to 20-fold
higher concentrations of esperamicins Al and C were required to produce
comparable amounts of DNA damage in cellular DNA compared to isolated
DNA. This was the case for all of the enediynes and, as discussed earlier, it
was likely due to factors such as sequestration of the drug in lipid membranes
in the cells or deactivation of the drugs in the cytoplasm.
To address the role of the cellular environment of DNA on the damage
produced by the enediynes, we have made quantitative comparisons of the
various lanes in Figure 3.1 following normalization of the damage frequency
data. In the inactive PGK1 gene, damage produced by esperamicin Al in cells
is reduced compared to that in naked DNA in two regions indicated by the
bars in Figure 3.1. This phenomenon is shown more clearly in Figure 3.2A,
in which regions of reduced damage lie between positions -330 to -200 and
positions -150 to +1, and they are flanked by regions in which cellular and
isolated DNA experience similar levels of damage. The sizes of the protected
regions (-130 and -150 base pairs) are consistent with the 146 base pair length
of nucleosome core DNA [3]. Furthermore, the identification of two
nucleosomes in this region of the inactive PGK1 gene is consistent with the
DNase I digestion studies of Pfeifer and Riggs [80].
The profile of esperamicin C-induced DNA damage in the inactive
PGK1 gene in cells is similar to that in isolated DNA (Figure 3.2B). There is
no general reduction in the level of damage between positions -330 to -200
and positions -150 to +1 as observed with esperamicin Al.
Mapping enediyne-induced DNA damage in the PGK1 gene by
conventional LMPCR. Studies were also performed with conventional
LMPCR to compare the in vivo and in vitro damage produced by enediynes,
since this method recognizes both single- and double-strand breaks [86].
Representative gels are shown in Figure 3.3 for esperamicins Al and C and
calicheamicin. As shown in the line graphs in Figures 3.4B and 3.4C,
calicheamicin and esperamicin C produce damage in both the putative linker
and core regions of the downstream nucleosome, while damage produced by
esperamicin Al occurs mainly outside the core DNA (Figure 3.4A).
There are several sites at which the damage frequency differs for
isolated and cellular DNA treated with calicheamicin and esperamicin C.
These sites may be located where the minor groove faces the histone proteins,
thus making the site inaccessible to the minor groove-specific enediynes. We
have observed this phenomenon in isolated core particles [28] and
reconstituted nucleosomes [76]. However, many of the sites are subjected to
similar levels of damage in both isolated and cellular DNA, which is
consistent with damage at sites where the minor groove faces away from the
histone proteins. Furthermore, there is no generalized suppression of the
damage between positions -150 and +1 as observed with esperamicin Al.
The reproducibility of the results is demonstrated in Figures 3.3 and
3.4A. In Figure 3.3, duplicate samples of esperamicin Al-damaged isolated
(lanes 1) and cellular DNA (lanes 2) are shown. While there are some minor
bands that differ between the duplicate lanes, probably due to statistical
sampling errors with low levels of damage [84, 86], the majority of bands are
of similar intensity in each lane. Data beyond position -80 was not used for
analysis due to unreliable amplification of long fragments by conventional
LMPCR, as discussed later. Of greater importance, I have indicated the ratios
of the level of esperamicin Al-induced DNA damage in cellular DNA to that
in isolated DNA in Figure 3.4A. The damage ratio at each site is an average
value (+ SD) for three different experiments. The relatively small errors attest
to the accuracy of the data.
IV. Discussion
The goal of the present work was to test the hypothesis that different
enediynes would recognize different chromatin structures in living cells.
This hypothesis arose from our previous studies in isolated chromatin [28]
and reconstituted nucleosomes [76, 101], in which we observed that damage
produced by esperamicin Al was limited to the linker regions between
nucleosome cores. The basis for this linker selectivity was determined to be
intercalation by an anthranilate moiety [71, 75], which caused the drug to bind
poorly to the dynamically constrained DNA of the nucleosome core.
Consistent with this hypothesis was our observation that removal of the
anthranilate to form esperamicin C caused the drug to damage both the core
and linker DNA of the nucleosome. Furthermore, calicheamicin, another
nonintercalating groove binder, was also capable of damaging both the core
and linker DNA [28, 76].
The present results in whole cells confirm these in vitro observations.
In the two nucleosome core-sized regions upstream of the inactive human
PGK1 gene, damage produced by esperamicin Al, but not by esperamicin C
and calicheamicin, is reduced in cells compared to naked DNA, while
flanking regions (putative linkers) show similar levels of damage. One such
region of suppressed damage lies between positions -330 and -200, the other
between -150 and +1. The two nucleosome cores would thus be joined by
about 50 base pairs of linker DNA, which is typical for nucleosome linkers in
mammalian cells [3]. The second nucleosome core appears to end near
position +1, as suggested by the results with both conventional and modified
LMPCR (Figures 3.2 and 3.4).
The presence of two nucleosomes detected by esperamicin Al in the
inactive PGK1 gene and the absence of detectable nucleosomes in the active
PGK1 gene are consistent with the nuclease digestion studies of Pfeifer and
Riggs [80]. They observed DNase I hypersensitive regions spaced at roughly
10 base pair intervals between positions -330 to -200 and -90 to +50 in the
inactive gene. However, this spacing would require a -110 base pair linker
between the two nucleosomes, which is inconsistent with the observed linker
sizes of ~40-60 base pairs in vertebrate organisms and mammalian cells in
culture (reviewed in [3]). There are at least two explanations for this
discrepancy in the position of the downstream nucleosome. One is that
detergent-induced disruption of the cell and nuclear membranes, which is
required to allow entry of DNase I into the nucleus, causes sliding of the
downstream nucleosome(s). Such sliding has been observed by several
groups during nuclease digestions in isolated nuclei (reviewed in [3]). It is
also possible that portions of the DNase I digestion pattern were influenced by
factors other than accessibility of nucleosome core DNA, such as sequence
selectivity of the enzyme or the presence of other chromosomal proteins.
Confirmation of the nucleosome positions by micrococcal nuclease digestion
was not possible in the studies of Pfeifer and Riggs, probably due to the fact
that the region under study is very G-C rich and micrococcal nuclease shows a
marked preference for A-T rich sequences [80].
In all of my studies, I observed low levels of esperamicin Al-induced
damage in the nucleosome core DNA in vivo. This is likely due to transient
disruption of nucleosomal structure during DNA replication and repair.
Cells used in the present studies were monolayers at ~80% confluency, so it is
likely that some of the cells were in S-phase. While DNA transcription has
also been shown to disrupt nucleosome structure [48], the X86T2 cells used in
our studies contained only the inactive X chromosome. Thus the low levels
of nucleosome core DNA cleavage by esperamicin Al are not likely due to
transcription.
While the quantity of damage at each site is modulated by chromatin
structure in vivo, the positions of damage sites are remarkably similar to that
in naked DNA (Figures 3.1-3.4). This indicates that DNA in vivo retains
some of the structural features present in vitro. Specifically, the in vitro
sequence selectivity still plays a significant role in target selection by
genotoxins in cells.
It is noteworthy that, under my conditions, the LMPCR technique
modified for enediyne-induced DNA damage consistently resulted in longer
amplification products than conventional LMPCR. This allowed me to
examine longer regions of the PGK1 gene for the location of drug-induced
DNA breaks (compare Figures 3.2 and 3.4). The basis for this difference
appears to lie in the use of Sequenase for the primer extension step of
conventional LMPCR, since, in modified LMPCR, this step is eliminated by
direct ligation of damage sites to the linker DNA; subsequent steps are
identical in both techniques. Sequenase is a highly processive enzyme at 370C
[104]. However, first-strand synthesis was performed at 480C or above to
reduce non-specific amplification in conventional LMPCR [96] and it is
possible that the elevated temperature reduced the processivity of the
polymerase. Whatever the basis, LMPCR modified for enediyne-induced
DNA damage allows longer regions of DNA to be examined on a single
sequencing gel. The modified-linker technique is also applicable to the two
base pair overhangs produced by other enediynes (e.g., C-1027; [60, 88]), as
long as the ends of the linkers are changed to account for the different
overhangs.
Enediynes offer several advantages over other methods for defining
nucleosome positions. The main advantage is their utility with intact cells,
since treatment of cells with enediynes does not disrupt the architecture of
the cell or nucleus. The enediynes are lipophilic molecules that readily
diffuse into cells. On the contrary, use of DNase I and micrococcal nuclease
requires cell permeabilization to allow access of the enzymes to nuclear
chromatin. In addition, DNase I-treated DNA often gives poor LMPCR
signals due to polymerase extension from the enzyme-induced 3' hydroxyl-
ended strand breaks [105], and micrococcal nuclease is biased toward AT-rich
regions [80]. Methidiumpropyl EDTA produces linker-selective DNA damage
in isolated nuclei [106], though evidence is lacking for its utility in whole
cells, and dimethyl sulfate, which readily penetrates the cell membrane, does
not footprint nucleosomes [107]. UV photofootprinting has the advantage of
minimal cell perturbation and good sensitivity, but it is limited to the
presence of dipyrimidines at the protein-DNA contact sites, and the need for
additional DNA treatment by T4 endonuclease V and E. coli photolyase [83].
In comparison to these other agents, treatment of intact cells by enediynes is
very straightforward and results in strand breaks with 5'-phosphate ends
compatible with LMPCR.
In conclusion, I have found that esperamicin Al can recognize locally
positioned nucleosomes on the inactive human PGK1 gene in vivo, while
esperamicin C and calicheamicin cleave both the core and linker DNA of the
nucleosome. The results of these structure/function studies are consistent
with in vitro models and serve as a benchmark for future explorations of the
role of genomic organization in the selection of targets by enediynes and
other genotoxins. The results also suggest that enediynes may prove useful as
chromatin footprinting reagents.
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V. Figures for chapter three
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Figure 3.1. Sequencing gel analysis of the DNA damage produced by
esperamicins in the inactive human PGK1 genes in vitro and in vivo.
Modified LMPCR was employed to amplify sites of enediyne-induced strand
breaks in the inactive PGK1 gene (X86T2 cells). Drug damage was studied in
both isolated DNA (lanes 1-3) and in intact cells (lanes 4-6). Lanes 1 and 4:
untreated controls; lanes 2 and 3: 0.1 gM of esperamicin Al and C,
respectively; lanes 5 and 6: 1 pM of esperamicin Al and C, respectively. The
amplified DNA was resolved on a 4% sequencing gel. The position in the
PGK1 gene is shown in the right margin and the proposed positions of two
nucleosomes are denoted by black bars. The weak cleavage apparent with
esperamicin C in the inactive PGK1 gene in cells (lane 6) was due to a low
drug concentration in this particular experiment; in other experiments with
higher drug concentrations (10 gM), the damage was similar to that in
isolated DNA (e.g., Figure 3.3).
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Figure 3.2. Comparison of DNA damage produced by esperamicin Al (panel
A) and esperamicin C (panel B) in the inactive human PGK1 gene. The gel
shown in Figure 3.1 was subjected to phosphorimager analysis and the
normalized data are presented as overlaying line graphs of damage frequency
along the human PGK1 gene. Black lines represent damage in isolated DNA
and gray lines represent damage in cells. The position in the PGK1 gene is
indicated below each graph and the proposed positions for two nucleosomes
are indicated below the graph.
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Figure 3.3. Sequencing gel analysis of the DNA damage produced by
esperamicins Al and C and calicheamicin in the inactive human PGK1 gene
in vitro and in vivo. Conventional LMPCR was used to amplify sites of DNA
damage produced by the enediynes in X86T2 cells (lane 2 in all panels) or in
DNA isolated from these cells (lane 1 in all panels). Esperamicin Al
concentrations were 0.1 gM (in vitro, lane 1) and 1 p.M (in vivo, lane 2);
esperamicin C concentrations were 0.4 pgM (in vitro, lane 1) and 10 pgM (in
vivo, lane 2); and calicheamicin concentrations were 0.1 p.M (in vitro, lane 1)
and 4 gM (in vivo, lane 2). The amplified DNA was resolved on a 6%
sequencing gel. AG and CT are Maxam-Gilbert sequencing standards. The
numbers on the right indicate the position in the human PGK1 gene. Please
note that a lane to the right of the CT sequencing standard in the esperamicin
Al panel and a lane between the calicheamicin-treated samples were
removed for clarity.
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Figure 3.4. Comparison of DNA damage produced by esperamicin Al (A),
calicheamicin (B), and esperamicin C (C) in the inactive human PGK1 gene.
The gels shown in Figure 3.2 were subjected to phosphorimager analysis and
the normalized data are presented as an overlay of line graphs of damage
frequency along the human PGK1 gene. Black lines represent damage in
isolated DNA and gray lines represent damage in cells. The numbers above
the peaks in Panel A represent the average ratios of the level of esperamicin
Al-induced DNA damage in cellular DNA to that in isolated DNA at each
site; the indicated errors are standard deviations for n=3. The position in the
PGK1 gene is noted below the graphs along with the proposed position of the
nucleosome.
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CHAPTER 4
THE ROLE OF TRANSCRIPTION FACTORS
IN ENEDIYNE TARGET SELECTION
I. Introduction
Transcriptionally active genes in eukaryotic nuclei exist in a
decondensed state of chromatin structure that allows access of transcription
factors and polymerases to their recognition sequences [3, 4]. Active
chromatin is characterized by stretches of open, nucleosome-free regions
bound by transcription factors (Chapter 1). Since the binding of transcription
factors is so fundamental to chromatin structure in active genes and it
represents the next level of complexity beyond the DNA helix, its effects on
enediyne target selection is addressed in this chapter.
The binding of transcription factors to their recognition sequences
alters DNA structure and dynamics [108]. The structures of several
transcription factor-DNA complexes have been solved, and there are models
for other proposed structures [45]. Our understanding of the interactions
between transcription factors and their cognate DNA sequences has reached
the sophistication of the nucleosome structure. With this in mind, I have
undertaken structure-function studies with enediynes to define the effects of
transcription factors on genotoxin target selection.
The promoter of the human PGK1 gene is an ideal model to study
active chromatin. Unlike inducible genes that require transient modification
of the nucleosomal structure, the active PGK1 maintains nucleosome-free
regions bound by putative transcription factors [109]. Such stable rather than
fluctuating chromatin structure facilitates the interpretation of in vivo DNA
damage patterns produced by genotoxins.
On the basis of footprinting studies, Pfeifer and coworkers have
identified several putative transcription factor binding sites in the active
PGK1 gene, including a CCAAT-binding protein, nuclear factor 1 (NF1)-like
protein, and GC-box binding proteins [80]. Previous biochemical studies have
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demonstrated that the binding of these factors to their cognate DNA
significantly alters the local environment of the DNA. For example, NF1 was
shown to completely embrace the circumference of the DNA helix [47], while
CCAAT and GC-box binding proteins bind in the major groove and bend the
DNA helix [110-113]. Therefore, these transcription factors in the human
PGK1 promoter provide an excellent model to study the effects of different
types of transcription factors on enediyne target selection.
I have mapped the DNA damage produced by calicheamicin and
esperamicins in the active human PGK1 gene in vivo. A comparison of the
damage in the same gene in its purified form and in cells indicated that DNA
damage in vivo is modulated by transcription factor binding. Esperamicin
Al-induced DNA damage is suppressed at sites within all transcription factor
footprints, but it is enhanced at several sites flanking the footprints. This
damage enhancement is also observed with esperamicin C and calicheamicin.
Furthermore, damage caused by esperamicin C and calicheamicin is
suppressed in the NF1- like site but not within the CCAAT- and GC boxes.
These observations are consistent with the types of drug-DNA and protein-
DNA interactions among the participating molecules. The results
demonstrate that both sequence selectivity and chromatin structure are
important in defining target selection by enediynes in vivo.
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II. Materials and Methods
Materials and cell lines. Calicheamicin yI1 and esperamicin Al and C
were provided by Dr. George Ellestad (Wyeth-Ayerst Research) and Dr. Jerzy
Golik (Bristol-Myers Squibb), respectively. Chinese hamster-human hybrids
containing an active human X chromosome (cell line Y162-11C) were
provided by Dr. Stanley Gartler (University of Washington, Seattle) [52]. Cells
were grown as a monolayer in RPMI 1640 with 10% fetal calicheamicin serum
and 40 pg/ml Gentamicin [52]. A clone of the upstream region of the human
PGK1 gene, pBSHPGK1, was provided by Dr. Judith Singer-Sam (City of Hope
Medical Center, Duarte, CA) [102].
Treatment of cells with enediynes. Cell treatment was as described
before (Chapters 2). After conversion of abasic sites to strand breaks by
putrescine, DNA samples were ethanol precipitated and redissolved in 10
mM HEPES, 0.1 mM EDTA (pH 7.7) at 1 mg/ml. The usage of HEPES instead
of Tris for DNA storage was recommended to limit background oxidative
damage [114].
Treatment of purified DNA with enediynes. DNA reactions were as
described before (Chapters 2). After ethanol precipitation, DNA samples were
finally stored in 10 mM HEPES, 0.1 mM EDTA (pH 7.7) at 1 mg/ml.
DNA sequencing reactions were performed as described (Chapters 2).
LMPCR. We used the following primers in the 5' region of the human
PGK1 gene: CGTCCAGCTTGTCCAGC (+134 to +118, primer BI);
TCCAGCGTCAGCTTGTTAGAAAGCG (+123 to +99, primer B2);
TGGGGAGAGAGGTCGGTGATTCGGTCA (+80 to +54, primer B3). The
sequences of the blunt linker and linker primer were as described elsewhere
[85]. Conventional LMPCR was used to amplify DNA sequencing reactions,
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while modified LMPCR was used to amplify drug-induced DNA damage.
Both methods were performed as described in Chapters 2 and 3.
After PCR amplification, half of each sample was resolved on a 6%
sequencing gel. Electroblotting and hybridization were performed as
described before [95]. The hybridization probe was made by repeated primer
extension from a cloned PGK1 template (pBSHPGK1) using primer B3 and
Taq polymerase [103]. Hybridized membranes were subjected to
phosphorimager analysis (Molecular Dynamics).
Data analysis. In order to compare damage frequency in isolated and
cellular DNA, I performed the experiments with drug concentrations that
produced roughly similar levels of DNA damage in the two situations. This
necessitates a higher drug concentration for treating cells than isolated DNA.
I then performed phosphorimager analysis essentially as described elsewhere
[76]. Each pixel value was first divided by the sum of the total pixel values in
the lane to account for lane-to-lane variations in sample loading.
Normalized pixel values in each lane were then plotted as a line graph. Line
graphs of the same sample from different sequencing gels (due to varied
running time to resolve different-sized fragments) were combined so that the
overlapping signal intensities were the same. The combined line graphs
from in vitro and in vivo drug treatment were presented as an overlay to
better visualize differences between the two substrates.
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III. Results
DNA damage by esperamicin Al in the active PGK1 gene. The damage
produced by the DNA intercalator esperamicin Al in naked DNA and in cells
containing an active PGK1 is shown in the right half of Figures 4.1 and 4.2,
and summarized in the overlaid line graphs in Figure 4.3A. The positions of
the putative transcription factors are derived from the in vivo DNase I and
dimethyl sulfate (DMS) footprinting studies of Pfeifer and coworkers [53, 80,
115]. In all cases, damage produced by esperamicin Al in cells is reduced
compared to naked DNA within the putative transcription factor binding
sites. In other words, in vivo damage suppression regions colocalize with
transcription factor footprints [53, 80].
While damage within the transcription factor footprints is suppressed,
there is an enhancement of cellular damage by esperamicin Al in regions
between transcription factor binding sites (asterisks in Figures 4.1, 4.2, and
4.3A).
DNA damage by esperamicin C in the active PGK1 gene. I also
compared in vivo and in vitro damage produced by esperamicin C, an Al
analog missing the deoxyfucose-anthranilate intercalator. Esperamicin C also
exhibits increases in cellular DNA damage in the region between NF1 and
CCAAT-binding sites (Figures 4.1 and 4.3B). These sites are identical to those
noted earlier for esperamicin Al. Therefore, it appears that the enhancement
of damage in the regions between transcription factors is not dependent on
DNA intercalation.
Within the transcription factor binding sites, damage by esperamicin C
in cells is suppressed in the middle of the putative NF1 site, but not in the
CCAAT- and GC-binding sites. In fact, damage in the two GC-boxes is
enhanced in cellular DNA (asterisks in Figures 4.1 and 4.3B). The
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enhancement of damage within protein footprints by esperamicin C is in
direct contrast to the suppressed damage in the same regions by esperamicin
Al (compare Figures 4.3B and 4.3A).
DNA damage by calicheamicin in the active PGK1 gene. A comparison
of damage produced by calicheamicin in cells and isolated DNA is shown in
the left half of Figure 4.2 and the line graph in Figure 4.3C. Once again, two
sites of enhanced damage are observed in the regions between bound
transcription factors (indicated by asterisks). In addition, one site of enhanced
damage is observed within the downstream GC-box. On the other hand,
damage in cells is suppressed within the putative NF1 site.
Compared to the esperamicins, calicheamicin damage sites are fewer in
number, probably due to its extended sugar side chain which increases the
sequence selectivity of the molecule [116]. This may explain the lack of
damage in the CCAAT site and the upstream GC-box. In the -400 bp PGK1
promoter region studied, one hotspot of calicheamicin damage was detected
at position -224 in naked DNA. The sequence context of this damage hotspot
is shown on the top of Figure 4.4. Position -224 lies at the 3'-end of a run of
eight purines, which is typical of calicheamicin damage hotspot reported in
the literature (Figure 4.4). In cellular DNA, two calicheamicin damage
hotspots were detected, one at position -224 and the other at -165, both of
which are located in the region between the putative GC- and NFl-sites
(Figure 4.3C).
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IV. Discussion
The results with the active human PGK1 promoter indicate that
genotoxin damage in vivo is modulated by transcription factors. The cellular
and DNA damage data for three structurally different enediynes are
summarized in the line graphs in Figure 4.3, where in vivo damage (gray
lines) is overlaid on in vitro damage (black lines). Several conclusions can be
drawn from these comparisons. First, cellular DNA damage by esperamicin
Al is inhibited within the putative transcription factor binding sites, but
enhanced between the binding sites. Secondly, these sites of damage
enhancement are also observed with esperamicin C and calicheamicin.
Finally, DNA damage produced by both esperamicin C and calicheamicin in
cells is suppressed within the putative NF1 site but enhanced in the GC-boxes.
I will now discuss these results in light of the altered DNA accessibility,
dynamics, and conformation caused by binding of these transcription factors.
Previous studies have demonstrated that the binding of transcription
factors to their cognate sequences significantly alters the local environment of
the DNA [108]. These alterations include steric hindrance [41], constraints on
DNA dynamics [117], and changes in DNA conformation [118]. The
ubiquitous transcription factor Spl regulates a variety of genes by binding to
the GC-boxes in vivo [112]. Spl family proteins belong to the zinc-finger
family of DNA binding proteins [119] that bind to the major groove of DNA
and induce an asymmetric bend directed towards the major groove, with a
bend center located towards the 3' end of the GC box [113]. Another family of
transcription factors, CCAAT/enhancer-binding proteins (C/EBP), bind to the
consensus CCAAT sequences [111]. They belong to the leucine zipper family
and are proposed to bind to the major groove of DNA by a "scissors grip"
model: the paired set of basic peptides track DNA in opposite directions along
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the major groove, forming a molecular clamp around DNA [110]. The C/EBP
family of proteins were shown to induce a small directed DNA bend of 1-4
degrees toward the minor groove [120]. Finally, the DNA binding behavior of
the NF1 family of proteins was studied in vitro by footprinting with dimethyl
sulfate (for G contacts), ethylnitrosourea (for phosphate contacts), and
potassium permanganate (for T contacts) [47]. The NF1 protein almost
completely surrounds the double helix, establishing a large number of
contacts with the bases and backbone [47].
The DNA damage results obtained with calicheamicin and
esperamicins are consistent with the binding modes of these transcription
factors, which is discussed in more detail below.
Damage modulation within transcription factor binding sites. Within
the boundaries of the putative transcription factor binding sites [53, 80],
damage produced by the intercalator esperamicin Al is reduced in cells
compared to naked DNA. This may be explained by steric hindrance and/or
constraints on DNA dynamics upon protein binding. This is analogous to the
results with nucleosomes in inactive chromatin, in which damage produced
by esperamicin Al is suppressed in the core DNA (Chapter 3). Reduced
interaction with DNA intercalators has been observed both in transcription
factor-DNA complex [117] and in nucleosome core DNA [29-32].
On the other hand, for minor groove agents calicheamicin and
esperamicin C, binding of proteins to the major groove might not inhibit
drug-DNA interactions. Cellular damage in the core of the putative NF1
binding sites is reduced for both calicheamicin and esperamicin C, consistent
with NF1 contacts in both the major and minor grooves [47]. This damage
inhibition is not observed in the CCAAT site and GC-boxes, consistent with
the major groove binding of these two factors.
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Furthermore, I observed an enhancement of drug-induced DNA
damage by the two minor groove agents in the putative Spl binding sites (GC-
boxes) in vivo (Figures 4.3B and 4.3C). One possible explanation is that Spl
binding bends the DNA towards the major groove [113], making it a better
target for calicheamicin. Our previous studies with reconstituted
nucleosomes revealed a 4-fold increase in calicheamicin-induced damage at a
site of sharp DNA bending near the dyad axis of the nucleosome [76]. This
site is located with its minor groove facing away from the histones [76],
therefore the direction of the bend is towards the major groove, similar to the
type of bend in Spl-DNA complexes. Alternatively, protein-induced DNA
bending may simply create an optimal minor groove width for enediyne
binding, since minor groove width was shown to be important in target
selection by both calicheamicin [77, 121] and esperamicin [122].
Damage enhancement between transcription factor binding sites.
While effects on DNA damage within protein binding sites varied according
to structures of enediynes and protein-DNA complexes, the hypersensitivity
of damage in sequences flanking transcription factor binding sites was
observed with both groove binding and intercalating enediynes. This
indicates that such damage enhancement is not dependent on the presence or
absence of an intercalator but rather is more likely related to some other effect
of the protein-DNA interactions. Pfeifer et al. observed that these same
regions in PGK1 were hypersensitive to DNase I [80]. Two possible
mechanisms may explain these observations: (1) the regions are free of
proteins and thus more accessible to genotoxins than the rest of the DNA; or
(2) DNA in these regions has a unique conformation targeted by enediynes
and DNase I. Although these two mechanisms need not be mutually
exclusive, the fact that not all sequences flanking transcription factor binding
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sites are hypersensitive to enediyne- and DNase I-induced damage favors the
second mechanism.
What could be the unique conformation targeted by these genotoxic
agents? From structural studies of the enediyne- and DNase I-DNA
complexes, it appears that the minor-groove width and depth are important
parameters affecting the interactions of calicheamicin [121], esperamicin [122]
and DNase I [123, 124] with their recognition sequences. In addition, DNA
bending is important for the interactions of calicheamicin [78] and DNase I
[124] with their DNA targets. It is known that the transactivating domains of
many bound transcription factors interact with each other, causing the
intervening DNA to form a loop [45]. These interactions put mammalian
genes under multiple controls for the level of transcription activity [45]. Such
looping may induce DNA bending, change minor groove width and possibly
unwind the helix in regions between transcription factors. Calicheamicin [78]
and DNase I [125]target bent DNA, DNA intercalators prefer underwound
DNA [126-129], while all three enediynes and DNase I require a widened
minor groove for favorable binding [121-124]. Therefore, similar to the
enhanced damage observed within Spl binding sites, enhanced DNA damage
in flanking sequences is consistent with a model in which target accessibility,
DNA dynamics, DNA bending and minor groove width are important factors
affecting enediyne target selection in vivo.
Both sequence selectivity and chromatin structure determine enediyne
target selection in vivo. The results with the human PGK1 indicate that
esperamicin Al and C share similar sequence selectivities (Figures 4.1 and
4.3). Calicheamicin, with its extended sugar side chain, displays a higher
degree of sequence selectivity [116] that results in fewer damage sites and at
different locations (Figure 4.3). The sequence selectivity of calicheamicin is
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determined by its sugar side chain [130], which targets flexible DNA sequences
and bend the DNA upon binding [131].
Several examples in the studies illustrate that enediyne target selection
in vivo is determined by both sequence selectivity and chromatin structure.
The first example is in regard to the calicheamicin damage hotspot in the -400
bp PGK1 promoter region studied. In naked DNA, one hotspot of
calicheamicin damage was detected at position -224. In cellular DNA, two
damage hotspots are detected: one at position -224 and the other at position -
165, both of which lie in the region between GC-box and NFl-binding sites
(Figure 4.3C). Position -224 is consistent with a common feature of
calicheamicin damage sites: the drug targets the 3'-end of a purine tract
(Figure 4.4). According to Salzberg et al., this target selection is due to the
preference of calicheamicin for bent or flexible sequences [78, 131]. Position -
165 does not lie at the end of a purine run and is a weak damage site for
calicheamicin in vitro. However, damage in this site is increased in vivo.
The site is located in the flanking region near the end of the NF1 site (Figure
4.3C). Therefore, both the in vitro sequence selectivity and in vivo chromatin
structure may determine the location of calicheamicin damage hotspots in
cells.
The second example of the importance of both sequence context and
chromatin structure comes from a comparison of DNA damage within the
two GC-boxes. An increase in damage by calicheamicin was observed only in
the downstream GC-box (Figure 4.3C). Esperamicin C, which has different
sequence selectivity than calicheamicin, exhibit an increase in damage in both
GC-boxes in vivo (Figure 4.3B). Spl, which binds to GC-boxes, can tolerate
considerable sequence variations while retaining function as well as three-
dimensional structure [119]. The two GC-boxes, although containing the
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"GGGCGG" consensus sequence [112], have different sequence contexts. The
fact that the structure and dynamics of DNA are significantly affected by
flanking sequences [132] may explain the lack of enhancement of
calicheamicin-induced damage in the upstream GC-box. Analogous to this
situation, Yu et al. found that histone-induced DNA bending alone cannot be
responsible for defining the damage site in nucleosomal DNA, since there
was no similar increase in calicheamicin damage one helical turn on the
other side of the nucleosome dyad [76]. Calicheamicin thus appears to select a
combination of both sequence-dependent conformation and protein-induced
structural alteration.
In vivo applications of enediynes: footprinting and transcription
modulation. The results of the present studies suggest that enediynes may
prove useful as footprinting reagents for the study of chromatin structure and
as modulators of transcription factor binding and functioning.
Along with the previous results with nucleosomes, the suppression of
cellular damage by esperamicin Al within transcription factor binding sites
indicates that this drug is an effective footprinting agent for defining
chromatin structure in intact cells. As discussed earlier (Chapter 3), enediynes
offer several advantages over other agents. The main advantage is their
utility with intact cells, since treatment of cells with enediynes does not
disrupt the architecture of the cell or nucleus. Also, the resulting DNA
double strand breaks are directly ligatable to modified linkers for the LMPCR
procedure developed in Chapter 2.
With regard to the modulation of transcription factor binding and
functioning, my studies suggest that unlike DNA intercalators, the minor
groove agents can still interact with DNA within the transcription factor-
DNA complex. In fact, the interactions between esperamicin C and
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calicheamicin with DNA in the GC-boxes are enhanced in vivo (Figures 4.3B
and C), suggesting that these agents could be used to inhibit transcription
factor binding and function. The oligosaccharide portion of calicheamicin
was shown to inhibit both the binding of transcription factors and
transcription [133]. The dimerized form of the calicheamicin oligosaccharide
was also synthesized and demonstrated to interfere with transcription factor
function [130]. The enediyne portion of the antibiotic contributes to the drug-
DNA interaction by increasing binding energy and widening the spectrum of
the target sequence [116]. The results from the present studies suggest that at
-10 rM concentrations, calicheamicin binding is enhanced within the Spl
binding site in vivo. This concentration is lower than most of the in vitro
concentrations used to demonstrate the inhibitory effect towards transcription
factor binding in the earlier studies with calicheamicin oligosaccharides [130,
133]. Therefore, the deactivated form of the total calicheamicin, which bind
to its target DNA with the same sequence selectivity and energy as the parent
calicheamicin [116], may be a better transcription inhibitor.
In conclusion, I have found that enediyne-induced DNA damage in
the active human PGK1 gene in vivo is modulated by bound transcription
factors. Transcription factors suppressed damage by esperamicin Al, but only
minor groove binding transcription factors suppressed damage by
esperamicin C and calicheamicin. Some major groove binding factors even
enhanced damage caused by esperamicin C and calicheamicin. Enhancement
of damage was also observed with all three enediynes between transcription
factor binding sites. These results are consistent with a model in which target
accessibility, DNA dynamics, DNA bending and minor groove width are
important factors affecting enediyne target selection in vivo.
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V. Figures for chapter four
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Figure 4.1. Sequencing gel analysis of the DNA damage produced by the
esperamicins in the active human PGK1 gene in vitro and in vivo. The left
four lanes contain duplicate samples of cellular DNA or isolated DNA
damaged by esperamicin C, 20 pM and 2 pM, respectively. The right four
lanes contain duplicate samples of cellular DNA and isolated DNA damaged
by 2 gM and 0.4 gM esperamicin Al, respectively. These two different drug-
treated samples are separated by a no-drug control lane (lane 0) and by
Maxam-Gilbert TC and GA sequencing markers. The LMPCR-amplified DNA
was resolved on an 8% sequencing gel, electroblotted onto a nylon
membrane, and hybridized with a human PGK1 probe. The positions in the
PGK1 gene are shown in the right margin and the positions of putative
transcription factors are denoted by open rectangles; transcription factor
positions were defined by Pfeifer and coworkers by DMS and DNase I
footprinting [53, 80, 115]. Sites of enhanced damage in vivo are denoted with
asterisks.
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Figure 4.2. Sequencing gel analysis of the DNA damage produced by
esperamicin Al and calicheamicin in the active human PGK1 gene in vitro
and in vivo. Cells were treated with 14 or 8 pM calicheamicin and 2 pM
esperamicin Al (duplicate samples), while isolated DNA was treated with 0.4
and 0.1 gM calicheamicin and 0.4 jiM esperamicin Al (duplicate samples).
Lane 0 is the no-treatment control, and TC an GA lanes are Maxam-Gilbert
sequencing reactions. The LMPCR-amplified DNA was resolved on an 8%
sequencing gel, electroblotted onto a nylon membrane, and hybridized with a
human PGK1 probe. The positions in the PGK1 gene are shown in the right
margin and the positions of putative transcription factors are denoted by open
rectangles. Sites of enhanced damage in vivo are denoted with asterisks.
Please note that a lane between the calicheamicin- and esperamicin Al-
damaged samples was removed for clarity.
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Figure 4.3. Comparison of enediyne-induced DNA damage in the active
human PGK1 gene. The gels shown in Figures 4.2 to 4.3 were subjected to
phosphorimager analysis and the data are presented as overlaid line graphs of
relative damage frequency along the human PGK1 gene, as described in
Materials and Methods. Black lines represent damage in isolated DNA and
gray lines represent damage in cells. The position in the PGK1 gene and the
proposed positions for transcription factors are indicated below each graph in
panels A (esperamicin Al), B (esperamicin C) and C (calicheamicin). Damage
enhancement sites in cellular DNA compared to naked DNA are indicated by
asterisks. Two in vivo calicheamicin damage hotspots, one at position -224
and the other at -165, are also indicated in panel C. The data for esperamicin
C from position -63 to +1 in panel B are derived from additional sequencing
gels (gels not shown).
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Figure 4.4. Sequence context of calicheamicin damage hotspots. The hotspots
for calicheamicin damage in human PGK1 are listed together with a
collection of calicheamicin recognition sequences from the literature. Clearly,
calicheamicin has a tendency to recognize the 3'-ends of purine runs
(underlined). Position -165 is the damage hotspot in cellular DNA but not in
isolated DNA. Both positions -224 and -165 lie between the GC-box and the
NF1-site in the active PGK1 in vivo.
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CHAPTER 5
THE ROLE OF DNA METHYLATION
IN ENEDIYNE TARGET SELECTION
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I. Introduction
Modification of mammalian DNA by methylation at the C5 position of
cytosine plays a critical role in both the regulation of gene expression [134-136]
and in cancer [137]. Given the known effects of cytosine methylation on
DNA structure and dynamics, I have examined its effect on DNA damage
produced by two structurally-related enediyne antitumor antibiotics,
esperamicins Al and C [56, 65, 138].
Cytosine methylation occurs in the underrepresented CG dinucleotides
in eukaryotic cells. While 1-2% of the genome consists of clusters of
nonmethylated CG sequences, mainly in the 5' regions of certain genes,
approximately 70% of CG dinucleotides are methylated [135]. The general
observation is that transcriptionally active regions are undermethylated in
comparison to their inactive counterparts in other cells. For the human
PGK1 gene, all the CpG dinucleotides are methylated in the inactive copy
while none is methylated in the active copy [53]. Thus, the human PGK1 is a
good model to examine the effect of DNA methylation on genotoxin-induced
DNA damage. There are exceptions to the association of methylation with
transcriptional silencing since methyl cytosine also occurs in active genes
such as p53 [139].
Although the mechanism by which cytosine methylation causes
changes in gene expression is unclear, it is believed to involve differential
recognition of methylated DNA sequences by proteins due to changes in DNA
conformation or by a direct methyl group-protein interaction ([12], Chapter 1).
Regarding the former hypothesis, cytosine methylation causes changes in
DNA structure and dynamics that include helical unwinding [15], increased
base stacking and helical stability [16], reduction in major groove charge
density near the methyl group [17] and, in certain sequence contexts,
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modulation of DNA bending [18-20]. These effects may account for the
propensity of methylated CG repeats to induce the formation of Z-DNA [140].
The changes in DNA structure and dynamics associated with cytosine
methylation also affect the interaction of small molecules with DNA. Both
benzo[a]pyrene diol epoxide [21] and mitomycin C [22] show enhanced
reactivity with methylated sequences while damage produced by bleomycin
[23] and N-methyl-N-nitrosourea [24] is inhibited by cytosine methylation.
However, the molecular basis for this altered reactivity remains unclear.
To better understand the role of cytosine methylation in the selection
of DNA targets by small molecules, I have undertaken studies with two
enediynes, esperamicins Al and C. Enediynes are extremely potent cytotoxins
that produce high levels of double-strand DNA damage by forming a
benzenoid diradical intermediate that binds in the minor groove and abstracts
hydrogen atoms from the deoxyribose backbone (Chapter 1). While they
share a common mechanism for damaging DNA, enediynes differ in the
structure and arrangement of functional groups attached to the enediyne core.
For example, esperamicin Al binds in the minor groove of DNA with
intercalation of its anthranilate moiety [71, 75], while removal of the sugar-
anthranilate to produce esperamicin C results in a shift in the chemistry of
the DNA damage [71, 141]. In spite of this structural difference, esperamicins
Al and C have similar preferences for damaging CG dinucleotides among
other recognition sequences [57]. These two analogs thus provide an
opportunity to investigate the relationship between cytosine methylation and
DNA intercalation.
I found that cytosine methylation in CG sequences increases the
reactivity of esperamicin Al. However, it was also observed that damage
produced by esperamicin C, the nonintercalating analog of esperamicin Al,
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was enhanced by DNA methylation at multiple methylated but not single
methylated CpG site noted with esperamicin Al. The results with the
esperamicins illustrate the complexity of methylation-induced alterations of
DNA reactivity and suggest that the altered reactivity extends beyond the CG
sequence.
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II. Materials and Methods
Materials and cell lines. Esperamicin Al was generously provided by
Dr. Jerzy Golik, Bristol-Myers Squibb. Esperamicin C was prepared by acid
catalyzed methanolysis as described elsewhere [71]. Chinese hamster-human
hybrids containing an active (cell line Y162-11C) or inactive (cell line X86T2)
human X chromosome were provided by Dr. Stanley Gartler (University of
Washington, Seattle) [52]. Cells were grown as a monolayer in RPMI 1640
with 10% fetal calicheamicin serum and 40 pg/ml Gentamicin [52]. A
plasmid (pBSHPGK1) containing a fragment of the upstream region of the
human phosphoglycerate kinase gene (PGK1) was provided by Dr. Judith
Singer-Sam, City of Hope [102].
Treatment of purified DNA with enediynes. Genomic DNA was
purified using a QiaAmp blood kit and dissolved in 50 mM HEPES, 5 mM
EDTA, 10 mM glutathione (pH 7.0) at 0.1 mg/ml. An aliquot of calicheamicin
or esperamicin in methanol was added (final methanol concentration <1%),
and the reaction was allowed for 30 min at 370C. The drug-damaged DNA
was treated with putrescine as described in the previous Chapters. DNA
samples were then ethanol precipitated and redissolved in 10 mM HEPES, 0.1
mM EDTA (pH 7.7) at 1 mg/ml.
For DNA sequencing reactions, purified genomic DNA was
concentrated by ethanol precipitation to 5-10 mg/ml. Maxam-Gilbert
sequencing reactions were performed according to an LMPCR-optimized
protocol [91]. 5-methyl-cytosine is resistant to Maxam-Gilbert sequencing
reactions [87]. Thus, a gap in the sequence ladder of the methylated DNA as
compared to non-methylated DNA indicates sites of DNA methylation [86].
LMPCR and data analysis. We used the following primers in the 5'
region of the human PGK1 gene: AAGTCGGGAAGGTTCCTT (-238 to -221,
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primer Al); AAGGTTCCTTGCGGTTCGCGGCG (-230 to -208, primer A2);
CGGCGTGCCGGACGTGACAAAC (-212 to -191, primer A3). The sequences
of the blunt linker and linker primer were as described elsewhere [85].
Conventional LMPCR (described in Chapter 2) was used to amplify DNA
sequencing reactions as well as drug-treated DNA, since it amplifies both SS
and DS damage.
After PCR amplification, half of each sample was resolved on an 8%
sequencing gel. Electroblotting and hybridization were performed as
described before [95]. The hybridization probe was made by repeated primer
extension from a cloned PGK1 template (pBSHPGK1) using primer A3 and
Taq polymerase [103]. Hybridized membranes were subjected to
phosphorimager analysis (Molecular Dynamics).
Phosphorimager analysis was performed essentially as described
elsewhere [142]. I accounted for minor differences in the levels of DNA
damage in different DNA samples and for lane-to-lane variation in gel
loading. To do this, I normalized the phosphorimager signal intensities in
each lane so that damage in both DNA substrates was the same at cytosine -
143. This cytosines resides in a run of pyrimidines (bottom of the gel in
Figure 5.1), and is not methylated in either DNA substrate. The validity of
the normalization process is illustrated by two points. First, the expectation of
equivalent amounts of damage in the non-methylated regions has firm
foundations in our previous studies [142]. Second, normalization of the data
to this non-methylated damage site resulted in the same damage in either
substrate in virtually every other non-methylated sites (Figure 5.2).
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III. Results
The effect of cytosine methylation on esperamicin-induced DNA
damage was studied in the promoter region of the human PGK1 gene. In
Figure 5.1, both the Maxam-Gilbert sequencing markers and drug-treated
samples are amplified by conventional LMPCR techniques to examine both
single-strand and double-strand breaks produced by enediynes. An additional
band in the C-reaction lane of the unmethylated DNA confirms the presence
of methylated Cs in the methylated DNA, as methylated Cs are resistant to
Maxam-Gilbert reactions [87]. The positions of the methylated Cs are
indicated by the asterisks next to the C-reaction lane (Figure 5.1). At cytosine
position -125, which is in the middle of several methylatable CG-repeats,
DNA damage by esperamicin Al and C are enhanced in the methylated DNA
compared to their unmethylated counterpart. Calicheamicin-induced lesions
are also enhanced in methylated DNA, although this is a relatively weak
damage site for calicheamicin.
Quantitative comparisons of these damages are expressed in Figure 5.2.
To account for minor differences in lane-to-lane variation in gel loading, we
normalized the phosphorimager signal intensities in each lane so that
damage in the non-methylated cytosine -143 in both DNA substrates was the
same. Methylation-dependent increase of esperamicin Al-induced damage is
apparent in cytosine positions -125 and -99 (panel A). There is also a
methylation-dependent enhancement at -119, although the LMPCR signals in
this site is rather weak. Esperamicin C-induced damage is enhanced in
multiple methylated cytosines -125 and -119, but not in singly-methylated
cytosine -99 (panel B). The enhancement of damage is observed only at
methylatable sites, since damages are the same at sites where there is no
methylation differences. One anomaly is at guanine -100, in which LMPCR
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signal is apparently enhanced in the unmethylated substrate (Figure 5.1.).
This difference was not observed with direct DNA damage (discussed below).
To control that the observed differences are indeed caused by the drugs
and not by the LMPCR procedure, we have also studied the direct DNA
fragmentation caused by esperamicins in a cloned fragment of the human
PGK1 gene [142]. Cytosines in CG sequences were uniformly methylated
using Sss I methylase and verified by Maxam-Gilbert sequencing reactions
[143]. Both non-methylated and methylated PGK1 fragments were 5'-end
labeled by 32P, and DNA damage were directly visualized on sequencing gels
[142]. In Figure 5.3, damage patterns examined by LMPCR is shown above the
PGK1 sequences (as in Figure 5.2), while damage patterns detected by direct
sequencing gel analysis of the PGK1 fragment is indicated underneath the
nucleotide sequences. It is evident that: (1) the patterns of damage identified
by either method are very similar, especially the sites of damage are the same;
(2) methylation-dependent enhancement of damage at positions -125, -119
and -99 for esperamicin Al and at -125 and -119 for esperamicin C are
consistent. There is a 1.5 to 2-fold increase in damage produced by
esperamicin Al at both CG repeats and a single CG sequence, while damage
enhancement with esperamicin C are observed at CG repeats only. One
difference between the two methods was observed at position -119, however.
The LMPCR produced a very weak signal at this site compared to direct
damage. The LMPCR signal of the Maxam-Gilbert sequencing maker is also
weak at this site (Figure 5.1).
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IV. Discussion
The role of DNA methylation in the selection of DNA targets by small
molecules has been the subject of several studies, e.g., with benzo[a]pyrene
diol epoxide [21], mitomycin C [22], bleomycin [23], and N-methyl-N-
nitrosourea [24]. Here I demonstrate that methylation enhances the damage
produced by two equilibrium-binding DNA-cleaving molecules, esperamicins
Al and C. Both enediynes bind in the minor groove and share similar
sequence selectivities. However, they differ structurally in that esperamicin C
does not possess the intercalating anthranilate of esperamicin Al. The results
with these structural analogs illustrate the complexity of methylation-
induced alterations of DNA reactivity.
There are several effects of cytosine methylation on DNA structure that
could influence the interactions of small molecules with DNA. These
include helical unwinding [15], increased base stacking and helical stability
[16], reduction in major groove charge density near the methyl group [17]
and, in certain sequence contexts, modulation of DNA bending [18-20].
Methylation-induced torsional flexibility or helical unwinding could explain
the increased binding of esperamicin Al since intercalators unwind the helix
upon binding and prefer to bind to the underwound helix of negatively
supercoiled DNA [126-129]. This effect would be consistent with the
observation of Denissenko et al. that cytosine methylation increases adduct
formation by benzo[a]pyrene diol epoxide [21]. However, plasmid unwinding
studies with esperamicin C suggest that the drug does not alter DNA twist
[71]. Esperamicin C would thus not be expected to be sensitive to
methylation-induced changes in DNA twist unless such changes affected
other features of DNA structure, such as minor groove width, thereby
creating a more attractive binding site for the drug. A similar argument could
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also be made for the methylation-induced increase in cross-linking by the
nonintercalating mitomycin C [22].
In studies with mitomycin C, Johnson et al. proposed that the
enhancement of mitomycin C cross-linking by cytosine methylation is due to
an electronic effect transmitted by hydrogen-bonding between the methyl
group and the N2 of guanine [22]. It could be argued that such local
alterations in minor groove charge density increase the binding of
esperamicins Al and C at position -125 in the PGK1 sequence (Figure 5.3).
However, this could not be the case at position -99 (Figure 5.3) where
esperamicin Al-induced damage is enhanced by cytosine methylation while
damage produced by esperamicin C is not.
Alternatively, axial flexibility or curvature could be involved in the
enhancement of esperamicin C-induced DNA damage by methylation. We
have observed that adenine methylation at the 3'-end of a target sequence for
calicheamicin, a related enediyne, increases drug-induced DNA damage by
1.5- to 2-fold (unpublished observations), an effect that may be related to the
propensity of calicheamicin to bend its target sequences [78]. While
esperamicin C is a structural analog of calicheamicin missing the terminal
sugar and aromatic ring, it does not share calicheamicin's selectivity for the
3'-end of purine tracts [77, 78].
Regardless of the local changes in DNA conformation caused by DNA
methylation, the effects appear to be transmitted along the helix over at least
several base pairs. Kim et al. have observed that CG repeats exert long-range
influences on DNA secondary structure [144], and it is possible that cytosine
methylation affects these long-range structural changes. Furthermore,
Hertzberg et al. demonstrated that the effect of methylation on bleomycin
cleavage can extend as far as 14 base pairs away from the methylated cytosine
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[23], while Hodges-Garcia and Hagerman observed that cytosine methylation
affects curvature of A-tracts up to three base pairs away [19]. Enediynes are
predicted to bind to DNA up to four base pairs away from their DNA damage
sites [75], in this case methylated CG sites. This suggests that the methylation-
induced changes in DNA conformation extend beyond the CG site to effect
drug binding.
The effects of methylation on the conformation of DNA targets of
esperamicins Al and C also appear to be dependent on sequence context, most
notably at the single CG site (-99 in Figure 5.3). At this site, damage produced
by esperamicin Al is enhanced, but there was no enhancement of
esperamicin C-induced damage. Such sequence-dependent effects have also
been noted in studies of methylated cytosine and DNA curvature [18, 19, 145].
My comparison of the data by the LMPCR and the direct damage
procedure indicated that the patterns of damage identified by either method
are very similar; especially the sites of damage and the degrees of
methylation-dependent damage enhancement are the same (Figure 5.3).
However, LMPCR produced a very weak signal at -119 compared to direct
damage. The LMPCR signal of the Maxam-Gilbert sequencing maker is also
weak at this site (Figure 5.1), suggesting this is an LMPCR-related artifact.
Another anomaly was observed at guanine -100, in which the LMPCR signal
intensity by esperamicin C is enhanced in unmethylated substrate. Such
enhancement is not found in the direct damage studies (Figure 5.3). This may
be caused by the LMPCR efficiency differences between the two substrates at
this particular site. Therefore, caution should be taken when comparing two
different damage sites or two differentially-methylated DNA substrates
(notice that methylation at cytosine -99 occurs adjacent to guanine -100). The
verification of methylation effects by direct damage studies served its
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necessary purpose in this regard. However, all of my previous LMPCR
studies were based on comparisons of damage in naked DNA and in cells.
LMPCR was performed on DNA substrates of the same methylation status,
and conclusions were made from comparing the same damage sites.
Therefore, the rare LMPCR anomaly observed here with different damage
sites or different methylation states should not be a problem in those studies.
In conclusion, the present studies broaden the repertoire of DNA-
damaging molecules for which target selection is affected by DNA
methylation. The results with esperamicins Al and C suggest that the rules
governing the effects of cytosine methylation on DNA structure and
dynamics are complex and remain to be elucidated. Future studies in our
laboratory will address the mechanism of cytosine methylation in enhancing
enediyne-induced DNA damage.
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V. Figures for chapter five
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Figure 5.1 The effect of cytosine methylation on enediyne-induced DNA
damage in the promoter region of the human PGK1 gene. Both the Maxam-
Gilbert sequencing markers and drug-treated samples were amplified by
conventional LMPCR techniques. Damages in isolated X86T2 DNA
(methylated) and Y162-11C DNA (unmethylated) were produced by three
enediynes as indicated above each lanes of drug-treated samples. The
"methyl +" and "methyl -" signs indicate methylated and unmethylated
DNA, respectively. Drug concentrations: esperamicin Al (1 gM), esperamicin
C (2 gM), and calicheamicin y (1 gM). TC, GA and C lanes are Maxam-Gilbert
sequencing markers. An additional band in the pyrimidine-reaction lane of
the unmethylated DNA confirms the presence of methylated cytosines in
X86T2 DNA, since methylated Cs are resistant to Maxam-Gilbert reactions
[87]. Therefore, an additional bands in lanes 4 vs. 3 indicates methylated
cytosines, which are marked by the asterisks to the left of the C-reaction lane.
The amplified DNA was resolved on an 8% sequencing gel, electroblotted
onto a nylon membrane, and hybridized to a human PGK1 probe. The
positions in the PGK1 gene is shown in the left margin, and the nucleotide
sequences are shown between the first two sequencing marker lanes. At
cytosine position -125 in the middle of several methylatable CG-repeats, DNA
damage by all three enediynes are enhanced in the methylated DNA
compared to their unmethylated counterpart, although this is a relatively
weak damage site for calicheamicin.
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Figure 5.2. Quantitative comparisons of the effect of methylation on DNA
damage caused by esperamicin Al (panel A) and esperamicin C (panel B).
The gel in Figure 5.1 was subjected to phosphorimager analysis. To account
for minor differences in lane-to-lane variation in gel loading, signal
intensities were normalized so that damage in the unmethylated cytosine -
143 (near the bottom of Figure 5.1) in both DNA substrates was the same.
Damage intensities were plotted over the human PGK1 sequence between
positions -140 to -94. Only the bottom strand of the PGK1 sequence was
plotted due to the unidirection of the gene-specific primer. The height of the
bar at each position in the PGK1 sequence is proportional to the damage
intensity. The black bars and gray bars indicate damage intensities in
methylated and unmethylated DNA, respectively. The numbers above the
bars represent average ratios of the damage frequency in methylated DNA to
that in unmethylated DNA from two independent experiments; the indicated
errors represent deviations about the mean for duplicate samples.
Methylated cytosines are denoted with asterisks.
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Figure 5.3. Frequency of DNA damage produced by esperamicin Al (panel A)
and esperamicin C (panel B). Data from both the LMPCR procedure
(presented above the nucleotide sequences) and from direct damage in a
cloned human PGK1 fragment (presented underneath the sequences) were
included. The LMPCR data above the nucleotide sequences were plotted the
same way as in Figure 5.2. The direct damage data utilized a cloned fragment
of the human PGK1 gene as DNA substrate and Sss I methylase to methylate
cytosines in all CG sequences in vitro [142]. Both non-methylated and
methylated PGK1 fragments were 5'-end labeled by 32P, and DNA damage
were directly visualized on DNA sequencing gels [142]. Damage intensities
were plotted over the human PGK1 sequence between positions -140 to -94.
The height of the bar at each position in the PGK1 sequence is proportional to
the damage frequency. The black bars and gray bars indicate damage
intensities in methylated and unmethylated DNA, respectively. The
numbers under the bars in the direct damage data represent average ratios of
the damage frequency in methylated DNA to that in unmethylated DNA; the
indicated errors are standard deviations for n-3. Methylated cytosines are
denoted with asterisks.
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CHAPTER 6
DEVELOPMENT OF TECHNIQUES TO MAP
LOW LEVELS OF DNA BREAKS IN WHOLE CELLS
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I. Introduction
So far, my approach to studying the genomic targets of DNA-damaging
agents makes use of the human PGK1 as a model gene. These studies provide
significant insights into the effects of local chromatin structure and DNA
methylation on the target selection by genotoxins. However, the studies are
limited by two factors. First, even with the power of LMPCR, the observation
of gene-specific damage on DNA sequencing gels requires much higher levels
of chemical treatment than experienced by cells during chemotherapy or
environmental exposure. High drug concentrations could saturate potential
hotspots for DNA damage and cause damage in low affinity or low frequency
sites. Secondly, the conclusions are limited to the possible unique chromatin
structure of a single gene, and do not provide significant clues as to the
location of the damage sites in the entire nucleus.
It has become increasingly clear that genotoxic chemicals and other
damaging agents such as radiation do not damage DNA randomly in cells
[146, 147]. For example, many chemicals attack transcriptionally active DNA
more frequently than inactive DNA. Included among these are the
anticancer drugs bleomycin and neocarzinostatin [146]; the carcinogenic
aflatoxin B1, which targets the nucleolar rRNA genes [148]; and the classical
probes of chromatin structure, micrococcal nuclease and DNase I [3].
Therefore, hotspots of DNA damage may exist in the mammalian genome.
The ability to map low levels of DNA damage in the nucleus will provide an
opportunity to detect DNA damage hotspots in the genome.
To this end, I have developed a technique that is broadly applicable to
the mapping of low levels of DNA breaks in the entire genome. Rather than
screening a battery of model chromatin structures and genes, we will isolate
all damage sites from whole cells subjected to low levels of DNA damage.
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The isolated damage sites, collectively and individually, contain a wealth of
information about the characteristics of the DNA damage at all levels of
genomic organization, from nuclear location to local DNA structure.
Strategies to further manipulate these damage sites (amplification and
cloning) to form a "genomic damage library" will be discussed.
I have chosen calicheamicin as the model agent for these studies for
several reasons. Its unique mechanism of action, involving abstraction of
deoxyribose hydrogen by a diradical intermediate, results exclusively in lethal
double-strand (DS) lesions with high efficiency [70]. Second, it is a potent
genotoxin, ~103-fold more toxic than adriamicin [66] and has an LDs0 of ~30
pM in several human cell lines [66, 67, 149]. Even with the power of LMPCR,
I need to treat the cells with ~1 gM drug concentration in order to resolve
DNA damage along the PGK1 gene. The goal of the studies presented in this
Chapter is to develop techniques to isolate all DNA damage sites at much
lower concentrations than those used for the LMPCR studies.
As shown in Figure 6.1, the technique involves preserving the cellular
DNA by agarose embedment, in situ labeling of DNA damage with
biotinylated nucleosides, and affinity purification of DNA damage fragments
with streptavidin-coated magnetic beads (Dynabeads). After drug treatment,
cells are embedded in agarose to provide structural support and to prevent
mechanical damage to DNA during subsequent steps [150]. I then exploit the
3'-phosphatase activity of T4 polynucleotide kinase (T4 kinase; ref. [151]) to
convert calicheamicin-induced 3'-phosphates to 3'-hydroxyl ended fragments.
The 3'-ends of DS breaks can finally be labeled with biotinylated nucleosides
and terminal deoxynucleotidyl transferase (TDT).
The purification strategy we have devised, involves restriction enzyme
digestion to produce manageable-sized fragments, followed by affinity
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purification of biotin-labeled fragments by Dynabeads (Figure 6.1). The
purified damage fragments can be used to make DNA probes for mapping
DNA damage sites, or can be amplified and cloned for the generation of a
"DNA damage library".
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II. Materials and Methods
Materials and cell lines. Calicheamicin yII was provided by Dr. George
Ellestad (Wyeth-Ayerst Research). HeLa S3 cells were grown as a suspension
culture in Joklik modified Eagle's minimum essential medium with 10%
newborn calicheamicin serum (Sigma) and 1% penicillin/streptomycin
(Sigma). T4 kinase and TDT were obtained from New England Biolabs and
Amersham Life Science (formerly United States Biochemical), respectively.
Dynabeads (streptavidin-coated magnetic beads) and magnetic separator were
purchased from Dynal, Inc.
Drug treatment and agarose-embedding of cells. HeLa S3 cells were
grown overnight in cell culture media with 1 gCi/ml of 3H-thymidine, then
harvested the next day at -80% confluency and resuspended in phosphate-
buffered saline (PBS) at 107 cells/ml. An aliquot of calicheamicin in methanol
was added (final methanol concentration <1%), and the reaction was allowed
to proceed for 20 min at 370C. The drug-treated cells were next embedded in
agarose essentially as described before [150]. A suspension of the drug-treated
cells (100 l) was gently mixed with an equal volume of molten 1.6% low-
melting agarose in PBS at 370C (Type VII agarose, Sigma), and dispersed in a
plastic agarose plug mold (BioRad) with pipet tips that have been cut off 5
mm at the ends to minimize mechanical damage to cells. The mixture was
allowed to solidify for 10 min at 4°C, after which agarose blocks were gently
pushed out of the plug mold onto a glass slide. The agarose block was then
sliced into -1 mm3 "chops" using a slide cover glass. Such small chops of
agarose minimize processing time by permitting rapid diffusion of chemicals
and enzymes into the cells.
DNA purification and labeling in agarose. Cells embedded in agarose
chops were treated with 1% SDS in 10 mM Tris, 30 mM EDTA, pH 8, for 3 hr
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at room temperature by gently rotating samples. This treatment lyses
membranes, denatures nucleases, and removes a significant portion of the
cytosolic and nuclear proteins [152]. However, unlike proteinase K, SDS does
not cause strand breaks [152]. SDS was removed by 4 x 10 min washes in 10
mM Tris, 1 mM EDTA, 50 mM NaC1, pH 8 (TES buffer), and one wash in
water. Buffer exchanges with agarose chops were facilitated by using screen
caps (BioRad) fitted to 50 ml Falcon tubes perforated at the other ends. The
chops were then equilibrated with 3'-phosphatase buffer (0.2 M NaCl, 10 mM
MgC12, 10 mM DTT, 0.1 M MES, pH 6) twice for 10 min. T4 kinase (20 U) was
then added and dephosphorylation proceeded for 1 hr at 330C. The chops
were washed 4 x 10 min in TES and 2 x 10 min in TDT buffer (2 mM CoCl2, 0.2
mM P~-mercaptoethanol, 100 mM sodium cacodylate, pH 7.2). Biotinylated-
dCTP (4 gM, Gibco BRL) and TDT (17 U) were added and the labeling reaction
allowed to proceed for 1 hr at 330C. Labeling was followed by washes in TES (4
x 10 min), RNase A digestion (0.1 mg/ml, 330C, 1 hr), proteinase K digestion
(0.1 mg/ml, 330C, 1 hr), and washes in TES (4 x 10 min). After labeling, DNA
was digested with a restriction enzyme Dpn II, a 4-cutter enzyme that cut
genomic DNA to manageable-sized fragments (average size -300 bp).
Following digestion, the DNA fragments were removed from the agarose
chops by electroelution and stored in 10 mM Tris, 1 mM EDTA, pH 8 until
use.
Assays for the levels of biotinylation. An aliquot of each DNA sample
representing equal amount of DNA (by 3H count) were spotted on a neutral
Nylon membrane (New England Nuclear). The levels of biotinylation were
assayed by a Phototope detection kit (New England Biolabs) and following the
manufacture's protocol. The chemiluminescent signals were detected by X-
ray films and quantitated by a densitometor (BioRad).
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Optimization of DNA binding buffer. In order to affinity capture
minute amount of biotinylated DNA in the vast excess of non-biotinylated
DNA, optimal binding buffer is required to achieve maximal specific binding
and minimal non-specific binding. A biotinylated 100 bp double-stranded
DNA (generated by PCR reactions with a biotinylated primer and a non-
biotinylated primer) was 5'-end labeled with y 2P-ATP and T4 kinase [153].
Non-biotinylated 3H-labeled DNA was purified from HeLa cells grown in the
cell culture media with 1 Ci/ml of 3H-thymidine overnight. The
biotinylated or non-biotinylated DNA were incubated with sufficient
Dynabeads under various test buffers at room temperature for 30 min by
gently rotating samples. Washes in the same test buffer were performed by
flipping the samples 10 times in room temperature. Dynabeads were
concentrated on one side of the tube by the magnetic separator and each
supernatant was transferred to a new tube. Half of each supernatant was
mixed with 10-time excess volume of Scinti Verse I (Fisher Scientific) and
radioactivity was counted by a liquid scintillation counter (Beckman). The
washes were repeated until radioactivity in the last three supernatants had
reached background levels (i.e., any subsequent washes did not further elute
more radioactivity). The final Dynabeads were subjected to scintillation
counting, and the result of each sample was calculated as percentage of total
radioactivity remaining on the beads.
The presence of detergent, monovalent salt and salt concentrations
were among the factors considered in various test buffers. The following
buffers were tested: (1) TE (10 mM Tris, 1 mM EDTA, pH 8) + 1 M NaCI + 0.1%
Tween 20, (2) 6xSSC (0.9 M NaCl, 0.09 M Na3citrate, pH 7) + 0.1% Tween 20,
(3) TE + 1 M NaCI + 0.1% SDS, (4) 6xSSC, (5) TE + 3 M LiCi + 0.2% Tween 20,
(6) 20xSSC (3 M NaC1, 0.3 M Na3citrate, pH 7) + 0.2% Tween 20.
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Affinity purification of biotin-labeled DNA fragments. After labeled
DNA samples were electroeluted out of agarose chops, they were allowed to
bind to Dynabeads for 30 min at room temperature in the optimal binding
buffer (10 mM Tris, 1 mM EDTA, 1 M NaC1, 0.1% Tween 20, pH 8) with gentle
rotation. Non-biotinylated DNA was removed by repeated washing in the
binding buffer, until radioactivity in the last three supernatants had reached
background levels. Finally, an aliquot of the beads were used to quantitate the
amount of 3H-DNA remaining on the Dynabeads by scintillation counting.
The counts from calicheamicin-treated samples were then compared with
that from control samples.
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III. Results
3'-phosphatase-dependent TDT labeling of calicheamicin damage sites.
The relative levels of biotin labeling with and without the 3'-phosphatase
activity of T4 kinase is presented in Figure 6.2. The control cells embedded in
agarose chops displayed equal levels of labeling with and without T4 kinase.
This indicates that most of the background DNA breaks have 3'-hydroxyl
groups rather than 3'-phosphates at their ends. In the absence of T4 kinase,
labeling of calicheamicin-induced damage sites occurred at the level of the
control cells. With the 3'-phosphatase activity of T4 kinase, however, the
level of biotin labeling increased significantly in cells treated with 1 nM
calicheamicin. The kinase-dependent labeling of the drug-treated sample
indicates that most of the calicheamicin-damage sites in vivo possess 3'-
phosphate ends, which is in agreement with our in vitro studies [70]. The
results of these biotin labeling studies demonstrate that the agarose
embedment and kinase/TDT labeling strategy permits labeling of
calicheamicin-induced DNA breaks at low drug concentrations.
Optimization of DNA binding buffer. In order to achieve maximal
specific binding and minimal non-specific binding to drug-induced damage
sites, I tested the effects of detergents, monovalent salts and ionic strength on
the binding of a 32P-labeled biotinylated DNA as well as 3H-labeled non-
biotinylated DNA. Table 6.1 shows the percentages of radioactivity remaining
on the Dynabeads after extensive washes with each test buffer. We
hypothesized that the presence of detergent would minimize non-specific
binding to the beads. Indeed, with a non-ionic detergent Tween 20 at 0.1%,
the non-specific binding decreased from 0.0011% in buffer 4 to 0.00007% in
buffer 2. Meanwhile, Tween 20 did not sacrifice specific binding. Ironically,
the ionic detergent SDS decreased the binding of biotinylated DNA from
149
-70% to -20% (compare buffer 1 to 3). The presence of monovalent salts at
high concentrations (500 mM or above) was important to minimize non-
specific binding (data not shown). However, lithium chloride at 3 M (buffer
5) or sodium chloride at 3 M in 20xSSC (buffer 6) did not enhance specific
binding when compared to sodium chloride at 1 M (buffer 1) or 0.9 M (buffer
2). In conclusion, buffers 1 and 2 both afforded similar levels of specific and
non-specific binding. Since buffer I tended to have longer shelf life due to the
presence of EDTA, I decided to use it as the DNA binding buffer.
Affinity purification of calicheamicin-damage fragments. The
calicheamicin dose-response for both the biotin labeling and Dynabeads
purification is presented in Figure 6.3. Clearly, with increasing concentrations
of calicheamicin, more biotinylated DNA were captured on Dynabeads. At 1
nM calicheamicin, about 3 times more DNA was captured compared to non-
drug treated control. Also at this concentration only about 0.01% of the
starting DNA was captured on Dynabeads, thus representing a 104 fold
enrichment of drug-induced damage fragments.
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IV. Discussion
In this Chapter, I have presented a technique applicable to the mapping
of low levels of DNA breaks in the entire nucleus. Rather than screening a
battery of model chromatin structures and genes, we are now able to isolate
all damage sites from whole cells subjected to low levels of DNA damage.
The isolated damage sites contain a wealth of information about the
characteristics of DNA damage and can be used collectively or individually to
study the distribution of DNA damage at all levels of genomic organization,
from nuclear location to DNA fine structure.
The technique involves enzymatic labeling of DNA damage with
biotinylated nucleosides and affinity purification of DNA damage fragments
with streptavidin-coated magnetic beads (Dynabeads), since the binding
affinity between biotin and streptavidin (Kd=10 5 M) is near the strength of
covalent bonds [154]. For in situ labeling of DNA damage, two techniques
have traditionally been employed: nick translation (NT) and 3'-tailing with
terminal deoxynucleotidyl transferase (TDT). The former exploits both the 5'-
to-3' exonuclease and the polymerase activity of E. Coli DNA polymerase I
(DNA pol I) to incorporate labeled nucleotides at DNase I-induced nicks [153].
It has been used to study DNase I hypersensitive sites in nuclei and
chromosomes [155, 156]. However, NT labels only SS nicks. TDT does not
require a template and adds nucleosides to the 3'-ends of DS breaks, and to a
lesser extent SS breaks [157]. It has been employed to label apoptotic DNA
damage in whole cells (e.g., [158]). Other methods to label damaged DNA
exploit cellular repair enzymes to incorporate labeled nucleotides (e.g. [159]).
Drawbacks to these approaches include inefficient repair of DS lesions and
selective repair of transcribed genes [160, 161]. Because the focus of my study
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is DS breaks, I have chosen to use TDT to label calicheamicin damage sites
with biotinylated nucleosides.
However, there is an impediment to the enzymatic labeling of
oxidative DNA damage: the presence of phosphate and sugar residues on the
3'-ends of the DNA fragments. Indeed, 3'-phosphate-ended fragments
represent the bulk (-85%) of DNA damage occurring by calicheamicin and
esperamicin in the presence of naturally-abundant polyamines and lysine
amino groups in vitro [70, 71]. To overcome this limitation, I have exploited
the 3'-phosphatase activity of the T4 polynucleotide kinase [151]. The
combined strategy of dephosphorylation with T4 kinase and labeling with
biotinylated nucleotides and TDT is shown in Figure 6.1A.
The fact that labeling of calicheamicin damage sites was kinase-
dependent (Figure 6.2) proves the feasibility of our approach. It also
demonstrates that enediyne-induced DNA damage in cells is a direct result of
the drug and is not mediated by apoptosis, since apoptotic DNA damage
processes strand breaks with 3'-hydroxyl ends (e.g., [162]). It further rules out
topoisomerase II as a target for the drugs in vivo [163], since drug-induced
inhibition of topoisomerase II also results in strand breaks with 3'-hydroxyl
groups that would not require dephosphorylation for end-labeling [163].
The success of our strategy relies not only on the specific biotinylation
of calicheamicin damage sites, but also on an affinity purification system that
can capture biotinylated DNA with minimum background binding. The
presence of Tween 20 (0.1%) and monovalent salt (sodium chloride at 1 M)
helps to minimize non-specific binding to -0.00001%, while not sacrificing
specific binding (Table 6.1). On the other hand, the ionic detergent SDS (0.1%)
decreases specific binding from -70% to -20%, probably because SDS partially
denatures the streptavidin tetramer thus releasing some biotinylated DNA. It
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is known that the binding affinity to biotin is 10-1s M for native streptavidin
tetramer and only 10- M for streptavidin monomer [154].
The fact that only up to -70% of biotinylated DNA remained on the
beads in Table 6.1 is a reflection of the biotinylation efficiency of the
biotinylated primer used to generate the 100-bp DNA, since it is not
uncommon that the biotin modification during oligonucleotide synthesis is
only 50 to 70% efficient [164]. When an HPLC-purified biotin-dCTP was
added to the 3'-ends of DNA by TDT, 95% of the DNA was captured by
Dynabeads in our optimum DNA binding buffer (data not shown).
With our current approach, it is possible to detect the levels of DNA
damage at 1 nM for 10' cells/ml (Figure 6.3). The drug/DNA ratio in this case
is similar to the LD50 concentration of calicheamicin (30 pM for 10s cells/ml,
Gentest, personal communication). The purified damage fragments (104-fold
enrichment) contain a broad spectrum of calicheamicin-induced DNA
damage sites, and can be used to make DNA probes by random-primer
extension [165]. These probes can be used for mapping DNA damage at all
levels of genomic organization, from nuclear location (by fluorescent in situ
hybridization) to DNA fine structure (by dot-blot hybridization) (Figure 6.1C).
However, the presence of significant amounts of biotinylated DNA in
non-drug treated samples (Figures 6.2 & 6.3) may be problematic. Initial dot-
blot and fluorescence hybridization experiments with DNA probes generated
from isolated damage fragments showed no significant differences between
the drug-treated (1 nM) and the control samples for several sequences
including telomeres, matrix attachment regions and human ribosomal DNA.
The reasons for such similarity may be: (1) background DNA break fragments
represent about one third of damage fragments in the 1 nM calicheamicin
sample (Figure 6.3), masking any subtle differences between the two; and/or
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(2) there is indeed no significant differences between the two DNA
populations, at least not detectable by the kind of gross hybridization
experiments performed. In order to differentiate these possibilities, we need
to lower the amount of DNA fragments isolated from control cells in the
future.
The DNA fragments isolated from control cells stem from background
TDT labeling in these cells (Figure 6.2), and are most likely due to the
presence of background strand breaks and labeling of telomeres. At 1 nM
calicheamicin concentration, the average size of DNA fragments is 106 bp
(data not shown). Therefore, there are on average 103 double-strand (DS)
breaks per cell. Extreme care was taken to minimize DNA breaks introduced
during DNA purification, including embedding cells in low melting agarose
and using pipet tips with ends cut off. However, a living cell contains on the
order of 0I single-strand (SS) nicks due to endogenous DNA damage, DNA
replication and DNA repair [166]. These SS breaks can also be labeled by TDT,
although to a lesser extent than DS breaks [157]. Human telomeres, on the
other hand, exist as "DS breaks" with extended 3'-overhangs [167]. I have
found that these DS breaks are good substrates for TDT: dot-blot hybridization
experiments with isolated damage fragments from both control and drug-
treated cells showed more than 20-fold enrichment of telomere sequences
compared to total genomic DNA fragments (data not shown). Therefore,
telomeres are highly enriched in the isolated damage fragments by the
current protocol.
One way to minimize the labeling of background breaks and telomeres
in the future is by taking advantage of the modified linker used successfully
in the LMPCR studies (Chapters 2 to 4). However, in this case, the linker
would posses a biotin on one end (Figure 6.4). This double-strand linker will
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ligate only to calicheamicin-induced DS breaks or 3-nt 3'-overhangs, but not
background SS nicks or telomeres (without the compatible 3'-overhang). The
presence of double-strand (DS) breaks in living cells is much rarer,
presumably because DS breaks are more lethal to cells than SS damage [161].
The frequency of DS breaks with 3-nt 3'-overhangs, as produced by
calicheamicin, must be even rarer. Therefore, the majority of the background
breaks will not be labeled. Assuming the occurrence of breaks containing 3-nt
3'-overhangs is a thousand times less than the frequency of background
breaks in control cells (not an unreasonable assumption), this improved
strategy (Figure 6.5) may substantially decrease background labeling. This has
significant implications for the detection of calicheamicin-induced DNA
damage at sub-lethal drug concentrations.
Furthermore, the presence of a universal linker places the first primer
sequence adjacent to the DNA damage sites. If a second linker is ligated on
the other end created by a restriction enzyme, PCR amplifications by both
linker primers would be possible. The amplified fragments could be cloned
into TA Cloning vectors from Invitrogen [168] to form a "genomic damage
library" (Figure 6.5). Such a library would contain all the information
regarding the quantity and location of DNA damage sites at very low drug
concentrations. This will provide significant insights into the mechanisms of
genotoxin target selection. For example, calicheamicin induces severe
chromosome rearrangement in CHO cells (G. Ellestad, personal
communication). It would be of great interest to examine whether the
locations of DS break sites correlate with sites of chromosome rearrangement
in these cells. In addition, the DNA damage probes generated by the
techniques presented here could be used collectively for hybridization to
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GeneChips from Affymetrix to obtain "DNA damage patterns" across the
entire genome [169, 170].
In conclusion, a method has been developed to isolate calicheamicin-
induced DNA breaks at nanomolar drug concentrations. This represented a
104 fold enrichment of drug damage fragments. Further improvement of the
technique may make it possible to generate a collection of DNA damage sites
at sub-lethal drug concentrations. Such a "genomic damage library" would
prove useful to decipher the mechanisms of genomic target selection at the
level of the whole genome.
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Table 6.1.
Type of buffers
1 2 3 4 5 6
TE 6xSSC TE 6xSSC TE 20xSSC
NaC1 Tween NaCi LiCI Tween
Tween SDS Tween
Specific
binding 72.5±0.5 70±1 18±2 70 67 58
Non-specific
binding 1.6±1.0 0. 7±0.3 nt 11±1 nt nt
x104
Table 6.1. Buffer effects on DNA binding to Dynabeads. Specific binding was
tested with a 3P-labeled biotinylated DNA fragment, while non-specific
binding was tested with 3H-labeled HeLa genomic DNA. The numbers
indicate the percentages of radioactivity remaining on the Dynabeads after
extensive washes with each buffer. Errors represent deviations about the
mean for duplicate samples. nt = not tested. The following buffers were
tested: (1) TE (10 mM Tris, 1 mM EDTA, pH 8) + 1M NaC1 + 0.1% Tween 20,
(2) 6xSSC + 0.1% Tween 20, (3) TE + 1M NaCl + 0.1% SDS, (4) 6xSSC, (5) TE +
3M LiC + 0.2% Tween 20, (6) 20xSSC + 0.2% Tween 20.
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V. Figures for chapter six
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Figure 6.1. TDT labeling technique to capture low levels of DNA damage
fragments in whole cells. After drug treatment, cells are embedded in agarose
to provide structural support and to prevent mechanical damage to DNA
during subsequent steps. The 3'-phosphatase activity of T4 kinase is exploited
to convert calicheamicin-induced 3'-phosphates to 3'-hydroxyl ended
fragments. The 3'-ends of DS breaks can then be labeled with biotinylated
nucleosides and TDT. The purification strategy we have devised, involves
restriction enzyme digestion to produce manageable-sized fragments,
followed by affinity purification of biotin-labeled fragments by Dynabeads.
Non-biotinylated DNA is removed from the Dynabeads by extensive washes.
The purified damage fragments can be used to make DNA probes by random
primer extension. These probes can be used for mapping DNA damage at all
levels of genomic organization, from nuclear location (by fluorescent in situ
hybridization) to DNA fine structure (by dot-blot hybridization).
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Figure 6.2. Kinase-dependent TDT labeling of calicheamicin-damage ends.
Both 3H-thymidine-labeled control cells and cells treated with 1 nM
calicheamicin were embedded in agarose chops, and processed as described in
the material and method section. Half of the samples were treated with T4
kinase (20 U) for 1 hr at 330C. Afterwards, all samples were treated with
biotinylated-dCTP (4 p.M) and TDT (17 U) for 1 hr at 330C. Digestions by
RNase A (0.1 mg/ml) and proteinase K (0.1 mg/ml) and Dpn II (100 U) were
followed to cut genomic DNA to manageable-sized fragments (average size
-300 bp). The DNA fragments were removed from the agarose chops by
electroelution and stored in 10 mM Tris, 1 mM EDTA, pH 8. An aliquot of
each DNA sample representing equal amount of DNA (equal cpm of 3H) were
spotted on a Nylon membrane. And the levels of biotinylation were assayed
by a Phototope detection kit. The chemiluminescent signals were detected by
X-ray films and quantitated by a densitometor. The relative levels of biotin
labeling with and without the 3'-phosphatase activity of the T4 kinase is
presented. Error bars represent deviations about the mean for duplicate
samples.
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Figure 6.3. Calicheamicin dose-response of biotin labeling and affinity
purification. Both 3H-thymidine-labeled control cells and cells treated with
increasing concentrations of calicheamicin were embedded in agarose chops,
and processed as described in the material and method section. All samples
were treated with T4 kinase (20 U) for 1 hr at 330C and labeled with
biotinylated-dCTP (4 gM) and TDT (17 U) for 1 hr at 330C. Digestions by
RNase A (0.1 mg/ml) and proteinase K (0.1 mg/ml) and Dpn II (100 U) were
followed to cut genomic DNA to manageable-sized fragments (average size
-300 bp). The DNA fragments were removed from the agarose chops by
electroelution and stored in 10 mM Tris, 1 mM EDTA, pH 8. About half of
each DNA sample representing equal amount of DNA (equal cpm of 3H) were
allowed to bind to Dynabeads for 30 min at room temperature in the optimal
binding buffer with gentle rotation. Non-biotinylated DNA was removed by
extensive washes in the binding buffer. Finally, an aliquot of the beads were
used to quantitate the amount of 3H-DNA remaining on the Dynabeads by
scintillation counting. The percentages of total 3H-DNA remained on the
Dynabeads from two independent experiments were pooled and presented
with increasing calicheamicin concentrations.
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Figure 6.4. The structure of the modified biotinylated linker. This double-
strand linker has a randomized 3-nt 3'-overhang on one end and a biotin tag
on the other. It will ligate only to calicheamicin-induced DS breaks or a 3-nt
3'-overhang breaks, but not background SS nicks or DS breaks without the
compatible 3'-overhang. Therefore, the majority of the background breaks
will not be labeled. This improvement is expected to significantly decrease
the background labeling and aid the detection of calicheamicin-induced DNA
damage at extremely low drug concentrations.
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Figure 6.5. The improved ligation strategy to capture extremely low levels of
DNA damage fragments in whole cells. After drug treatment, cells are
embedded in agarose to provide structural support and to prevent mechanical
damage to DNA during subsequent steps. Alternatively, since the modified
linker is not compatible with background SS nicks, DNA is simply purified by
conventional method. The 3'-phosphatase activity of T4 kinase is exploited
to convert calicheamicin-induced 3'-phosphates to 3'-hydroxyl ended
fragments. The 3'-ends of DS breaks can then be ligated directly to the
biotinylated linker with randomized 3'-ends (A: ligation). The purification
strategy is the same as in Figure 6.1 (B: purification), which involves
restriction enzyme digestion to produce manageable-sized fragments,
followed by affinity purification of biotin-labeled fragments by Dynabeads.
Non-biotinylated DNA are removed from the Dynabeads by extensive
washes. In C: amplification and cloning, a second linker is ligated on the
other end created by the restriction enzyme. PCR amplifications by both
linker primers can follow. The amplified fragments can be cloned into TA
Cloning@ vectors (Invitrogen) to form a "genomic damage library". Such a
library would contain all the information regarding the quantity and location
of DNA damage sites at very low drug concentrations. This collection of
DNA damage fragments can be further studied by standard DNA mapping
techniques, from probe hybridization to DNA sequencing. This will provide
significant insights into the mechanisms of genotoxin target selection by these
DNA damaging chemicals.
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Appendix: Mathematical Derivations
1. Single-hit condition in the 400 bp DNA region analyzed by each primer set
is achieved by cleaving genomic DNA to an average molecular size of 6000 bp.
For simplicity, let us assume that in DNA damage experiments, each
phosphodiester bond in the DNA backbone is damaged with the same
probability P. Then the fragment sizes of the resulting DNA molecules
approach a certain distribution, as resolved on an agarose gel. In such a
distribution, the weight-average molecular weight Mw is approximately equal
to the molecular weight corresponding to mobility of the peak of the mass
distribution, and the probability of a bond being broken is the reciprocal of
half the Mw [171]. Thus, if the molecular weight corresponding to the
mobility of the peak mass distribution is 6000 bp as determined by agarose gel
electrophoresis, the probability P is 1/(6000/2), or 1/3000.
A DNA region of 400 bp will be examined with each primer set on a
sequencing gel. In such 400 phosphodiester bonds, the probability of having
"n" bonds broken is determined by the binomial distribution [172]:
Pn(1-P)N-n N!
P(n) = (N-n)!n! , where N = 400, and P = 1/3000.
Thus, P(0) = 0.875, P(1) = 0.117, and P(0) + P(1) = 0.992. This means that greater
than 99% of the DNA substrate receives less than or equal to one hit in any
400 bp region (i.e., single-hit condition).
The single-hit condition is maintained as long as the molecular weight
of the peak mass distribution is 6000 bp or greater. In practice, this is readily
satisfied by treating purified DNA with 1 gM or lower and whole cells with 10
pM or lower drug concentrations.
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2. Starting with 2 jgg of mammalian genomic DNA ensures the presence of at
least 100 molecules of each damage fragment.
A diploid mammalian genome contains approximately 6x10 9 bp, which
is equivalent to 6.8x10-12 grams [173]. Thus, 2 jgg of mammalian genomic
DNA represents about 2.94x10 5 cells or 5.88x105 autosomal gene copies. For
the purpose of my studies, I use 3x105 cells or 6x105 autosomal gene copies per
2 jig of genomic DNA, as did before in other studies [100].
As discussed above, genomic DNA damaged to peak mass distribution
of 6000 bp ensures single-hit conditions within the 400 bp region analyzed by
any gene-specific primer. Under these conditions, the probability P (any bond
being broken) is 1/3000. Consider an extreme situation, where damage occurs
randomly at every single nucleotide. The number of starting molecules at
every possible damage site is equivalent to the number of gene copies
multiplied by the probability of a bond being broken: (6x105 ) x (1/3000) = 200.
Thus, by starting with 2 gtg of DNA, there are at least 100 molecules of each
possible damage site in the beginning of ligation-mediated PCR.
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